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The science of nanotechnology that is involved in the treatment, diagnosis, monitoring and control 
of diseases is commonly referred to as nanomedicine. Nanomedicine is set to revolutionize drug 
delivery and development, especially for diseases such as cancer which is on an upward spiral. 
Technologies involving the manipulation of materials at an atomic level are shaping the direction 
of conventional therapeutic approaches, promising to improve areas of delivery, entrapment and 
sustained release. Gold nanoparticles (AuNPs), present with unique characteristics on the nano-
scale, exhibiting low toxicity, high biocompatibility, ease of surface design and unique optical 
properties. The combination of these factors promotes the extensive study for their use as drug and 
gene delivery vectors. Conventional chemotherapeutic drugs are limited in their efficacy, relating 
to factors of poor biodistribution, rapid in vivo degradation and lack of specificity. The nature of 
conventional therapeutic approaches gives rise to undesirable and often severe side effects, 
determining the duration and intervals between treatments. A development of a targeted drug 
delivery system, able to improve distribution and bioavailability to cancerous tissue whilst offering 
low off target cytotoxicity and a controlled release profile under appropriate conditions is urgently 
required.  
This study entails the chemical synthesis of AuNPs and their subsequent functionalization with 
two cationic polymers, chitosan and poly-l-lysine. Encapsulation and linear binding of respective 
polymers to 5-fluorouracil (5-FU) was investigated. Physico-chemical characterization studies 
were carried out on all synthesized nanoparticles and nanocomplexes through UV-visible 
spectroscopy, TEM, FTIR, ICP and Nanoparticle Tracking Analysis (NTA).  All nanoparticles and 
nanocomplexes appeared as polydispersed, small (<105 nm) spherical particles, with 
nanocomplexes exhibiting good colloidal stability (high positive zeta potentials). From the two 
polymers utilized and the two binding methods evaluated, the encapsulation method with chitosan 
exhibited superior 5-FU binding and release capacity, with a controlled release pattern observed 
over a selected period of time. The cytotoxicity trends of all nanocomplexes were investigated 
using the MTT and SRB cell viability assays in three human cancer cell lines, viz. Caco-2 (colon 
adenocarcinoma), HEPG2 (hepatocellular carcinoma), MCF-7 (breast adenocarcinoma) and a non-
cancer cell line, HEK293 (embryonic kidney). The AuNP nanocomplexes were able to exhibit 
significant dose dependent anticancer activity, with a specificity towards the cancer cell lines. A 
comparative study of AuNP-polymer:5-FU nanocomplexes against control polymer:5-FU 
complexes revealed that the Au containing nanocomplexes elicited greater anticancer activity, 
highlighting the versatility of gold nanoparticles in therapeutic drug delivery.  
v 
 
Overall, the above characteristics and biological activity show the immense potential of these 
AuNPs as suitable anticancer drug carriers in vitro, and with further studies and optimizations they 
could be extended to clinical cancer therapy. 
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The science of nanotechnology that is involved in the treatment, diagnosis, monitoring and control 
of diseases is commonly referred to as nanomedicine. Nanomedicine is set to revolutionize drug 
delivery and development, especially for diseases such as cancer which is on an upward spiral. 
Technologies involving the manipulation of materials at an atomic level are shaping the direction 
of conventional therapeutic approaches, promising to improve areas of delivery, entrapment and 
sustained release. Gold nanoparticles (AuNPs), present with unique characteristics on the nano-
scale, exhibiting low toxicity, high biocompatibility, ease of surface design and unique optical 
properties. The combination of these factors promotes the extensive study for their use as drug and 
gene delivery vectors. Conventional chemotherapeutic drugs are limited in their efficacy, relating 
to factors of poor biodistribution, rapid in vivo degradation and lack of specificity. The nature of 
conventional therapeutic approaches gives rise to undesirable and often severe side effects, 
determining the duration and intervals between treatments. A development of a targeted drug 
delivery system, able to improve distribution and bioavailability to cancerous tissue whilst offering 
low off target cytotoxicity and a controlled release profile under appropriate conditions is urgently 
required.  
This study entails the chemical synthesis of AuNPs and their subsequent functionalization with 
two cationic polymers, chitosan and poly-l-lysine. Encapsulation and linear binding of respective 
polymers to 5-fluorouracil (5-FU) was investigated. Physico-chemical characterization studies 
were carried out on all synthesized nanoparticles and nanocomplexes through UV-visible 
spectroscopy, TEM, FTIR, ICP and Nanoparticle Tracking Analysis (NTA).  All nanoparticles and 
nanocomplexes appeared as polydispersed, small (<105 nm) spherical particles, with 
nanocomplexes exhibiting good colloidal stability (high positive zeta potentials). From the two 
polymers utilized and the two binding methods evaluated, the encapsulation method with chitosan 
exhibited superior 5-FU binding and release capacity, with a controlled release pattern observed 
over a selected period of time. The cytotoxicity trends of all nanocomplexes were investigated 
using the MTT and SRB cell viability assays in three human cancer cell lines, viz. Caco-2 (colon 
adenocarcinoma), HEPG2 (hepatocellular carcinoma), MCF-7 (breast adenocarcinoma) and a non-
cancer cell line, HEK293 (embryonic kidney). The AuNP nanocomplexes were able to exhibit 




comparative study of AuNP-polymer:5-FU nanocomplexes against control polymer:5-FU 
complexes revealed that the Au containing nanocomplexes elicited greater anticancer activity, 
highlighting the versatility of gold nanoparticles in therapeutic drug delivery.  
Overall, the above characteristics and biological activity show the immense potential of these 
AuNPs as suitable anticancer drug carriers in vitro, and with further studies and optimizations they 
could be extended to clinical cancer therapy. 
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1.1   Introduction 
Cancer, a chronic worldwide disease, is characterized by uncontrolled cell division, mainly due to 
genetic aberrations1. The mechanism through which cancer develops, for many years has divided 
researchers due to the complexity of the disease. However, with the increased research into the 
genetics and biology of cancer, this is slowly unravelling, implicating genetic alterations, cell 
signaling pathways, replication and avoidance of apoptosis2. Current methods of treatment are 
dependent on the outcomes of clinical and pathological staging3, and include surgical resection, if 
the tumor is located in an area which is operable, followed by radiation or chemotherapy, to kill 
the remaining cancer cells4. Each method carries their own measure of risk. 
Chemotherapy involves the use of cytotoxic drugs, with the aim of targeting rapidly dividing cells, 
a fundamental characteristic of cancer cells5. Conventional anticancer drugs used in the treatment 
of cancer do provide some benefit, however, they show no specificity towards the tissue they act 
upon, resulting in severe and unwanted side effects6, such as hair loss, anemia, and lowering of the 
white cell blood count, which further drain strength from already ailing patients. Recent research 
has indicated that chemotherapeutic agents may also stimulate an antitumor immune response7, 
however a safer and targeted system would serve patients better. In addition to these side-effects, 
repeated administration of treatment is common, but does not guarantee remediation of cancer. 
The non-specificity of action, low levels of accumulation of the drug at the target site and their 
rapid metabolism in the body shortly after administration, are all obstacles which scientists must 
overcome if we are to successfully treat cancer and related diseases8.  
Hence, there is much room for treatment options to be improved upon. Essentially, drug delivery 
is what governs the effectiveness of therapeutic agents9 and a better understanding of the field will 
go a long way in improving the lives of the millions of patients, who are in battle with this dreaded 
disease.  The potential of classical and novel therapeutic agents is limited by their ability to be 
delivered both safely and efficiently to targeted tissue10. Further research must be conducted to 
gain a better understanding of the inner workings of efficient drug delivery systems11. Over the 




delivering their payloads to the targeted tissue. Many have shown promise in vitro, but have 
suffered setbacks due to unforeseen interactions and hurdles in in vivo studies. For these reasons, 
new methods for cancer therapy, especially in the field of nanotechnology are being developed, in 
the hope that they present with better outcomes. 
While nanotechnology has revolutionized areas of our lives such as entertainment and transport, 
they also show promise in advancing the fields of science and medicine. Nanotechnology is 
dedicated to developing, designing, constructing, and employing materials at the nanometer scale. 
Nanoparticles are advantageous, in that their characteristics can be altered to suit the desired 
requirement, without changing their actual chemical composition12. Gold is a precious metal, 
coveted for its luster, color and its value. Its favorable characteristics and the facile synthesis of 
gold nanoparticles, have led to their use as potential therapeutic agents and drug and gene delivery 
carriers.   
This study focused on chemically synthesizing gold nanoparticles via the citrate reduction method, 
conjugation of gold nanoparticles(AuNPs) with the cationic polymers, chitosan and poly-l-lysine 
via the methods of encapsulation and linear binding, and complete characterization of 
nanoparticles and nanocomplexes using physico-chemical methods. It was anticipated that the 
combination of gold nanoparticles with the cationic polymers would produce delivery systems 
with greater anticancer activity than administration of the drug on its own, in the cell lines tested. 
Cationic polymers were incorporated into the delivery vehicle due to their ability to stabilize the 
nanoparticles and serve as chemical linkers between the gold nanoparticle and the anticancer drug, 
5-fluorouracil (5-FU). These polymers have high densities of positive charges and were expected 
to impart favorable characteristics to the AuNPs for biological applications. Both chitosan and 
poly-l-lysine were investigated for their ability to entrap 5-FU efficiently and to release the 
anticancer agent under specific pH conditions.  The nanoparticle cytotoxicity’s and apoptosis 







1.2      Aim and objectives  
This study aims to synthesize, and fully characterize AuNPs, polymer functionalized AuNPs and 
their nanocomplexes with the anticancer drug 5-FU. The study further aims to determine, the 
effectiveness of the AuNPs and functionalized AuNPs as an anticancer drug delivery systems.   
The main objectives will be: 
• To chemically synthesize and characterize AuNPs.  
• To functionalize the AuNPs with chitosan and poly-l-lysine using two unique methods. 
• To evaluate the conjugation of 5-FU to the AuNP systems by binding efficiency studies.  
• To determine the pharmacokinetics of the AuNP delivery systems with regards to 
controlled drug release and final drug delivery.  
• To establish a cytotoxicity profile for the delivery systems in four selected cell lines, and 
determine if any apoptosis induction was achieved.  
 
 
1.3       Outline of thesis 
This thesis was written in the format of an introductory chapter followed by a literature review, 
two research papers and a concluding chapter. 
Chapter 1 is a brief introduction and background to the research topic, and provide the aims, 
objectives and outline of the thesis. 
Chapter 2 provides a detailed review of the literature. It also highlights the use of gold 
nanoparticles in delivery of therapeutic agents and what generated interest in this study. It 
highlights some of the commonly used techniques in the synthesis of gold nanoparticles, whilst 
also including information on stabilizing agents used, and the most likely mechanisms through 
which the nanoparticles enter the cells.  
Chapter 3 and 4 are written in the form of research papers, involving chitosan and poly-l-lysine 
functionalization of AuNPs, respectively. It highlights the design and synthesis of gold 
nanoparticles, focusing on their characterization using UV-vis, TEM, ICP, NTA and FTIR.  Drug 




assessed. The papers compare the encapsulation and linear binding for each polymer, with 
discussion and interpretation of all results.  
Chapter 5 concludes the thesis, highlighting and summarizing the results obtained. Future studies 
or recommendations are also outlined.  
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2.         Literature review 
2.1 Drug delivery 
Drug delivery is a captivating field of study, engaging the interest of researchers worldwide, both 
from an academic and industrial view point. This is largely due to the urgent need to address the 
many limitations associated with the delivery of drugs safely and efficiently, while minimizing 
their harmful side effects1. Drug delivery as a concept, can be summarized as the release of a 
bioactive agent, at a specific site under controlled and sustained release2. This definition however, 
is based on an ideal scenario and further research is required to meet the challenges of efficient 
drug delivery, thereby allowing classical and novel drugs to be used to their fullest potential. This 
can be achieved through the development and optimization of targeted and efficient drug delivery 
systems3, 4.  
It is of little consequence designing novel drugs or modifying classical formulations to increase 
activity, when the vectors responsible for their distribution remain ineffective5. Presently, many 
drugs are limited in their efficacy towards treating conditions due to issues of poor solubility 
resulting in chemotherapeutic agents being unable to penetrate biological membranes6-8, 
requirement of high dosages leading to increased toxicity towards healthy tissue, low levels of 
accumulation at the target site, their nonspecific delivery and action9, short plasma half-lives and 
rapid in vivo degradation10. The need to develop safe and efficient delivery vehicles has generated 
in great interest in the field, resulting in collaborations between researchers of various fields and 
disciplines8. 
In addition, the biology of solid tumors is such that cell division towards the center slows down 
drastically, effectively stopping, thereby limiting the ability of the chemotherapeutic agents to act. 
Furthermore, many chemotherapeutic agents are unable to penetrate deep into the tumor, limiting 
their effectiveness in eradicating the cancerous cells11, 12. A further obstacle includes the 
overexpression of P-glycoprotein on the surface of cancerous cells13, 14. This protein is termed a 
multidrug resistance protein, primarily as it prevents the accumulation of drugs within the cell, 




Presently the vast number of chemotherapeutic agents used in the treatment of cancer, work 
through destroying rapidly dividing cells17, one of the fundamental characteristics of cancerous 
tissue . This targeting system is largely ineffective, as many types of tissue in addition to neoplastic 
cells are known to divide rapidly, including those present in the digestive tract, hair follicles and 
bone marrow18, 19.  
Current methods of treatment show little differentiation between cancerous and healthy tissue20, 
the consequences being that such chemotherapeutic agents often result in unpleasant and severe 
side effects21. These include hair loss, anemia, decrease in white blood cells that leave patients 
vulnerable to infections through a suppressed immune system, organ dysfunction and mucositis 
that involve inflammation of the gastrointestinal tract lining. Such side effects limit the dose and 
intervals between treatments22, 23. 
An ideal targeted drug delivery system should possess the ability to  bind the therapeutic agent, 
protect the drug from in vivo degradation, transport the drugs in a safe and efficient manner to a 
specific cell, tissue or organ and successfully release the anticancer agent under the appropriate 
conditions24, 25, in comparison to classical methods, thereby reducing treatment costs through 
avenues including increased product shelf life and reduced concentrations needed to obtain 
positive outcomes26, 27. The development of unique drug delivery systems offers many advantages 
such as a greater degree of protection, whilst improving pharmacokinetics28, 29. This highlights the 
importance of developing novel drug delivery systems for the future, resulting in it being one of 
most important areas of drug research currently.  
The rapid advancement of nanotechnology in recent years is likely to have a substantial impact on 
the discovery and emergence of new drug delivery systems. Due to recent advancements in the 
field, it is not beyond reason to suggest that nanoparticles are the future of drug delivery, having 
the potential to become valuable therapeutic and diagnostic tools due to their varied applications 
in research and medicine30. In addition, the ease of modification associated with many 







There are a variety of classical anticancer drugs, which have been developed over the years. 
However, 5-fluorouracil (5-FU) is widely accepted as being the backbone of many 
chemotherapeutic techniques in the treatment of patients with late stage colorectal cancer.                  
5-fluorouracil was introduced as a chemotherapeutic agent more than 4 decades ago, currently the 
drug remains one of the more favored options and is included in majority of adjuvant 
chemotherapy for late stage colon cancer. Most chemotherapeutic regimes involve the use of a 
combination of drugs, 5-fluorouracil is often used in combination with levamisole or leucovorin32. 
Studies have revealed that 5-fluorouracil based combinational chemotherapy improves the survival 
rates of patients with stage III colon cancer33-35.  
Effectively, 5-FU is an analogue of the naturally occurring pyrimidine uracil, it is an 
antimetabolite, as seen in Figure 2.1, it contains a fluorine group, covalently attached to an uracil 
molecule 36. Research has previously demonstrated that rat hepatomas tend to favor incorporation 
of radiolabeled uracil when compared to normal tissue. These studies eluded to the fact that 
enzymatic pathways for the use of uracil and by extension analogs of uracil are different between 
cancerous and non-cancerous cells37. Building on this, with the inclination that analogs could be 







      Figure 2.1   Molecular structure of 5-Fluorouracil. 
 
Since 1957, great strides in elucidating the mechanism of action of 5-FU have been made. For 5-
FU to express its cytotoxic ability, it requires cellular uptake and metabolic activation. 5-FU is an 




and enzymes involved in anabolism and catabolism39. Upon entry into the cell, 5-FU undergoes 
anabolism into its cytotoxic equivalent via a number of pathways. The enzyme thymidine 
phosphorylase catalyzes the reversible conversion of 5-FU to 5-fluoro-2'-deoxyuridine (FdUrd)40, 
41. A second enzyme, thymidine kinase introduces a phosphate group onto the 5’-carbon present 
in the deoxyribose ring, resulting in 5-fluoro-2’deoxyuridine monophosphate (FdUMP). The de 
novo synthesis of thymidine 5’monophosphate from 2'-deoxyuridine-5’monophosphate is 
catalyzed by the enzyme thymidylate synthase. This is achieved through the transfer of a methyl 
group from 5,10-methlyenetetrahydrofolate. There have been two pathways identified in which 5-
FU is converted into a ribonucleotide viz. firstly uridine phosphorylase converts 5-FU into FdUrd, 
followed by the enzyme uridine kinase which catalyzes the formation of 5-fluorouridine 
monophosphate. The second pathway involves the direct transfer of a ribose 5’monophosphate 
from 5’phosphoribosyl-1-pyrophosphate to a 5-FU molecule via the enzyme orotate 
phosphoribosyltransferase. The 5-fluorouridine monophosphate first undergoes conversion to 5-
fluorouridine diphosphate then to 5-fluorouridine triphosphate by action of the enzymes nucleoside 
monophosphate and nucleoside diphosphate kinases. The latter is readily utilized by RNA 
polymerases, which incorporate it into RNA molecules. 
One of the main mechanisms of action exhibited by 5-FU is the inhibition of thymidylate synthase 
through action of FdUMP. Some of the consequences of the inhibition of thymidylate synthase 
include depletion of thymidine 5’monophosphate and thymidine 5’-triphosphate. This results in 
DNA synthesis ceasing and interference with DNA repair. Whilst there is an argument that cells 
can overcome the inhibition of thymidylate synthase, through salvage of extracellular thymidine, 
the levels of thymidine present in human plasma are insufficient42.     
Like many classical chemotherapeutic agents, whilst it has shown to be very effective in destroying 
cancerous cells, it shows little specificity, resulting in the systematic destruction of both healthy 
and cancerous tissue. However, due to its effectiveness, it is still a drug of choice and in use 
presently. However, the drug is administered intravenously, primarily due to the unpredictable 
bioavailability of the drug when administered orally. Numerous studies have reported on the 
cytotoxicity of this drug towards healthy tissue. In many cases it was reported that 5-FU has 





2.3 Nanotechnology  
Advancement in the field of nanotechnology has greatly impacted many medical and industrial 
fields 46. It involves the engineering and synthesis of materials, at a level of atoms and molecules47. 
Nanotechnology has been one of the most important influences on our social economy over the 
last century and can be compared to the effect the semiconductor or information technology has 
had over the years48. Recent advancements in the field has highlighted the possibility of 
breakthroughs in various areas including nanoelectrics, materials and manufacturing, 
biotechnology, medicine and healthcare. With such a vast array of possible applications, it comes 
as no surprise that expectations are high with many viewing nanotechnology as being the next 
industrial revolution49, 50. 
The use and interaction of nanotechnology with cellular and molecular components in medicine 
and healthcare is termed nanomedicine. The ability to manipulate matter at an incredibly small 
scale, often between 1 – 100 nm51, 52, offers many advantages which are not exhibited by their bulk 
counterparts, such as the capability of deeply penetrating tumors, areas that are not accessible to 
individual molecules or bulk solids 53. In addition, the creation of materials at this scale often 
results in unique and desirable chemical, physical and biological properties54, 55. 
At the nanoscale level, many semiconductors, metals and polymeric particles exhibit novel 
electronic, magnetic, structural and optical properties56. Such properties have enabled the science 
of nanotechnology to be applied across a variety of fields including diagnostics, therapeutics and 
imaging57. Nanotechnology has shown immense potential in being able to bind and transport drugs 
across those physiological barriers known to be difficult to traverse, such as the blood brain barrier. 
Researchers have shown that through coating nanoparticles with polysorbates, it is possible for 
drug loaded nanoparticles to be transported across the blood brain barrier, thereby enabling brain 
targeting after intravenous injection58.  
There is no doubt that nanotechnology is shaping the future especially in formulation of novel 
methods and application in science and medicine. Hence, it is now important to build frameworks 







Cancer is a disease that has been around for thousands of years with the earliest known medical 
description dating back to 2500 BC, in ancient Egyptian text. It was described there as a “a bulging 
tumor in the breast, like touching a ball of wrappings”. With regard to a form of treatment, it was 
written “There is none” 59.   
Thousands of years later, we are still searching for an effective form of treatment, with cancer 
becoming one of the leading causes of mortality worldwide60. However, since then tremendous 
strides have been made in attempting to understand the genetics and biology of tumors, with the 
general consensus being, that cancer develops from both genetic instability and exposure of cells 
to different micro-environmental factors61.  Simply, cancer is the uninhibited growth of cells, 
which results in cellular dysfunction due to the level of aggressive growth.  
Cancer is known to follow a multi-stage process62, from the initial emergence of cancer cells to 
clonal masses or tumors, and to the subsequent distribution of cancer cells from the primary tumor 
to distant organs or tissue via the blood and lymphatic systems through the complex processes of 
invasion and metastasis63, 64. Metastasis remains a challenge in terms of treatment and is a major 
cause of cancer related mortalities65. Cancer cells often undergo genetic mutations causing 
activation of their oncogenes and/or inactivation of their tumor suppressor genes, allowing the 
cells to evade growth suppressors, resist cell death, sustain proliferative signaling, encourage 
angiogenesis and replicative immortality and finally induce invasion and metastasis66. A schematic 
representation of the fundamental characteristics of cancer is shown in Figure 2.2.  One of the 
many challenges faced by researchers in the effective treatment of cancer is the combination of 
complex signaling pathways and multiple mechanisms which permit cancerous cells to evade 
programmed cell death.  
Drug delivery systems must meet certain requirements if effective cancer treatment is to be 
reached, viz. targeted delivery of the anticancer agent specifically to the tumor, thereby limiting 
cytotoxicity towards healthy tissue, increasing the bio-accessibility of the drug to the tumor tissues 
at the required concentrations, increasing circulation time of the drug, and protecting therapeutic 






Figure 2.2:  The hallmarks of  cancer, processes enabling tumor formation and metastasis 61. 
 
Colon cancer represents some of the highest mortality rates, and is the third most frequently 
diagnosed form of cancer with 1.36 million new cases reported in 2012 60, and a prominent cause 
of mortality in both men and women worldwide. Standard treatment options involve surgery, and 
either chemotherapy or radiation or both68. These options have shown to be effective, however 
they often result in severe side effects in patients69. In addition, these treatment options come with 
their own level of peril, such as radiotherapy which can result in complications such as soft tissue 
necrosis70 or spinal cord myelitis71. This highlights the need for non-invasive techniques in the 
treatment of cancer. Hence the challenge to formulate and design suitable drug delivery systems 
that can fulfill this need. 
 
2.5 Gold nanoparticles: A brief history 
Gold has fascinated man for centuries, wars have been waged and civilizations built around this 
precious metal. The history of gold dates back centuries, and during the middle ages it was believed 
that through experiments base metals could be converted into gold72. The quest to discover the 
secrets of creating gold laid down many of the principles of modern chemistry through discovering 
the physical and chemical properties of various substances73. 
As early at the 16th century, there was a belief among healers of the time, that if gold could be 




afford such luxuries began to drink gold and noticed that this gave their skin a sheen and which 
was highly desirable at the time. In ancient Egypt, 5000 years ago, gold was ingested to aid in 
mental, spiritual and purification of the body75.  
 
2.6 Gold in biomedical applications 
Gold nanoparticles have emerged as potential drug and gene delivery vehicles due to their 
multitude of favorable characteristics, such as their ease of synthesis and ability to be chemically 
functionalized with various groups76. The ability to conjugate gold nanoparticles with a number of 
therapeutic agents such as peptides, proteins, nucleic acids and drugs, allows for them to be used 
in various biomedical applications such as diagnostics, imaging and therapeutics77, 78. However, 
for these nanoparticles to become effective in cellular applications, the nanoparticles must exhibit 
efficient delivery to targeted cells, including controlled release of the drugs or genes under specific 
conditions.  
While in vitro studies are essential and will demonstrate the many capabilities of nanoparticles in 
delivering genes and drugs and other therapeutic molecules79, when introduced in vivo they are 
likely to illicit possible immune responses80, 81.  Hence, if nanoparticles are to safely and efficiently 
deliver their cargos, mechanisms must be created to negate these immune responses. This is not 
beyond comprehension, and with a thorough working knowledge of the various constraints 
involved, gold nanoparticles with purposefully designed morphologies and surface modifications, 
have the potential live up to current expectations82.  
Some of the many advantages of using gold nanoparticles in medicine is that they are bio-inert, 
essentially non-toxic and biocompatible, thereby making them an ideal choice as a starting material 
when designing a delivery vehicle83.  Furthermore, gold nanoparticles with varying hydrodynamic 
sizes have been easily synthesized with controlled dispersity84. The favorable sizes of gold 
nanoparticles adds to their arsenal, as they have the ability to deeply penetrate cells and tissues, 
making their possible uses in medicine far-reaching85. In addition, they possess unique properties, 
such as their ability to absorb and significantly scatter visible and near-infrared light upon 
excitation of their plasmon oscillation86. These properties can be manipulated to control the release 
of drugs, which was first reported in 2000, where drugs bound to plasmonically active particles 




Many drug delivery systems involving gold have been formulated to release their payload in either 
one of two ways viz. through biologically controlled factors such as pH environment of the cell or 
through external stimuli such as the application of light or radio frequencies88. 
Modification of particles at the level of atoms and molecules, changes the substances properties 
often resulting in unique characteristics. These unique characteristics are what set gold 
nanoparticles apart from their opponents. Gold nanoparticles have been shown to possess a larger 
surface to volume ratio, in comparison to other particles89. This is attractive as a single nanoparticle 
of gold will be able to carry a larger capacity of drugs, therapeutic agents or targeting moieties, 
making them more efficient as delivery vectors.  
In addition to the unique optical, magnetic90 and catalytic properties91 of gold nanoparticles, and 
their various sizes, they can be synthesized into a variety of shapes, such as rods, stars, diamonds 
or spheres.  Their applications are vast, ranging from chemical processing, to drug92 and gene 
delivery, and to imaging or diagnosis of cancer or other related diseases93. The introduction of 
cationic polymers to gold nanoparticles serves to further strengthen electrostatic interactions with 
drugs such as 5-Fluorouracil, enabling for a greater level of binding, in addition to increase stability 
in physiological conditions.   
 
 2.7  Gold nanoparticles and drug delivery 
As mentioned earlier, gold nanoparticles have attracted attention in recent years due to their many 
unique properties.  However, the ability to delivery drugs safely and efficiently to target sites such 
as the colon, lungs or brain requires more basic research. Gold nanoparticles, on their own, do not 
possess any targeting groups, or unique surface properties which allow them to be directed 
specifically to any tissue or to bind specific biomolecules such as nucleic acids. Their advantage 
lies in their ability to be functionalized with cell specific ligands, stabilizing agents94 and 
polymers92, among others. The ability to study the mechanism of functionalization, its 
optimization, and its effects on the bio-activity of gold nanoparticles may hold the key to successful 
drug delivery to a variety of tissues. In order for gold nanoparticles to be targeted, various ligands, 
aptamers, antibodies or proteins have been employed to modify the surface properties to provide 




However, this will not be limited to drug delivery, as better understanding of the inner workings 
of functionalization and targeting emerge, in theory any chemical or biomolecule may be 
introduced and delivered efficiently. Current research has illustrated that gold nanoparticles can 
be successfully functionalized using targeting ligands such as folic acid96 and galactose97. Such 
functionalization results in the accumulation of nanoparticles in target cells, allowing for their use 
in various applications including therapeutics, diagnostics and imaging57.  
 
2.8  Surface plasmon resonance of gold nanoparticles    
Gold is a metal which has fascinated man for centuries, and much of the attention it received stems 
from properties such as its depth of color, luster and resistance to oxidation. Gold nanoparticles 
possess unique optical properties which result in their intense color. The color of colloidal gold 
suspension is dependent on the shape and size of the nanoparticles, and their ability to interact with 
light results in these unique properties98. The shape of gold nanoparticles is important as it has an 
effect on the surface plasmon resonance(SPR), which in turn has an effect on the efficiency of the 
nanoparticles in various medical applications99. Through altering the shape of a nanoparticle, it is 
possible to adjust the SPR in the visible and near infrared regions. The surface plasmon resonance 
of spherical gold nanoparticles occurs in the middle of the visible wavelength, and by  changing 
the shape from spheres to rods or nanoshells, it is possible to shift the SPR closer to the near-
infrared (between 800-1200 nm)100, 101. Briefly, all metal nanoparticles possess a naturally 
occurring oscillating electromagnetic field, and the exposure of light to these nanoparticles results 
in an increase in the oscillation of the free electrons present in the metal. Due to the increased 
oscillation of the electrons, a charge separation occurs between the ionic lattice and the free 
electrons. The amplitude of the oscillation reaches a maximum at a specific frequency, resulting 
in the absorption of light102. This specific frequency can be determined through UV-vis analysis. 
There are several factors which are known to affect the surface plasmon resonance of a particle 
including the size, shape and composition of the specific metal in question. This unique ability, 
allows for these nanoparticles to be used in photothermal therapeutic schemes, such as the release 
of drugs once they have entered their site of action103. Furthermore, the presence of the gold 





2.9  Surface modification and zeta potential 
The surface chemistry of a nanoparticle is one of the determining factors directing their uses in 
specific applications. In the instance of drug delivery, a proper understanding of nanoparticle 
surface chemistry is imperative in determining whether successful conjugation can occur between 
biomolecules such as targeting ligands and the nanoparticle. Surface modification of nanoparticles 
with regard to drug delivery will determine the efficacy of the nanoparticle as a drug delivery 
vector. 
Surface modification is important primarily for four reasons viz. (1) to increase the circulation 
time of the nanocomposite which can also be achieved by slowing down the removal of the 
nanocomposite via the reticulo-endothelial system, (2) to allow for the attachment of targeting 
ligands and therapeutic agents such as drugs, (3) to stabilize the nanoparticle and preventing 
aggregation and (4) to reduce any cytotoxicity that could arise from the original capping ligands104. 
The term zeta potential is used to describe the electro kinetic potential in a colloidal suspension. It 
is a measure of the magnitude of charges on a nanoparticle. The zeta potential is also an indication 
of the surface potential, and so determines the magnitude of the electrical double layer repulsion. 
It is possible to generate a net electrical charge through ionizing surface functional groups present 
is a suspension of nanoparticles such as gold. Zeta potential analysis is one of the few methods 
available for characterizing the interaction between the surface of the nanoparticle and the 
substance it is suspended105. Essentially, if all particles present in a colloidal solution have larger 
zeta potentials, either negative or positive in magnitude, this results in stronger forces of repulsion 
between the nanoparticles, thereby preventing aggregation. In comparison, if particles have low 
zeta potentials, then there will be a reduction in the repulsive forces which exist between 
nanoparticles, resulting in unwanted interactions and aggregation. Two factors which greatly affect 
zeta potential are pH and conductivity of the medium the nanoparticles are suspended in106. Zeta 
potential has been widely used in pharmaceutical formulations for evaluation of stability.  
 
2.10 Synthesis of gold nanoparticles for drug delivery  
Since the ability of gold nanoparticles to function as drug or gene delivery vehicles is largely 
dependent on their size, shape and structure, the ability to produce and manipulate gold 




field.  The two most commonly used methods for the synthesis of gold nanoparticles viz. citrate 
reduction and the polyol reduction method, are described below. 
 
2.10.1. The citrate reduction method 
The citrate reduction technique, introduced by Turkevich in 1951, remains one of the most 
common methods for synthesizing gold nanoparticles for biomedical applications. The method 
involves the reduction of gold (III) chloride trihydrate with a reducing agent such as Trisodium 
citrate. It is a simple and cost effective method, allowing for the synthesis of gold nanoparticles in 
which size can be parametrically controlled, through changing the ratio of sodium citrate to gold 
salt. Nanoparticles produced are relatively uniform in shape and size distribution.  
The progress of the reaction can be monitored through observation of changes in color107,108. 
Initially the color will be a pale-yellow solution, transitioning to colorless, to dark blue, purple 
then finally a deep wine red hue. The color of the solution gives an indication of the size of 
nanoparticles present in the solution, with the change in color from blue to wine red being 
attributed to the reduction in size of the gold nanoparticles. Generally, the size of nanoparticles 
synthesized in this method range from 40 -100 nm, making it an ideal protocol for the synthesis of 
nanoparticles with biological applications in mind.  
It has been shown that the citrate ions have a dual purpose in this reaction. Firstly, they act as a 
reducing agent, assisting in the reduction of Au3+ to Au0, secondly they stabilize the nanoparticle 
through forming a layer of citrate ions around the surface of the nanoparticle107, 109. The citrate 
ions have a net negative charge, which they induce around the surface of the nanoparticle. This 
creates repulsive forces between the gold nanoparticles preventing undesirable interactions and 
aggregation. However, if the nanoparticles are suspended in a non-aqueous media, the 
nanoparticles will become unstable and aggregate. This is very undesirable and would limit the 
use of the nanoparticles in many applications. 
 
2.10.2  Polyol reduction method 
In this method, metal precursors such as oxides, nitrates and acetates are refluxed in ethylene 




in which nanoparticles are formed by nucleation and growth from the solution, with polyol acting 
a solvent for the inorganic compound. It has been shown that the size of nanoparticles produced 
through this method can be modified by altering the pH of the solution, with a decrease in pH 
resulting in a decrease in the size of nanoparticles, much like how the addition of larger volumes 
of sodium citrate will result in smaller nanoparticles in the citrate reduction method described 
previously.  
The above two methods have been successfully employed to synthesize gold nanoparticles of 
favorable characteristics, with the former being utilized in this study. However, the long-term 
stability of a colloidal solution is an important factor in creating efficient delivery systems, 
therefore a better understanding of the mechanisms by which the nanoparticles are stabilized is 
needed. 
 
2.11  Polymer modification and stabilization of gold nanoparticles 
The stability of gold nanoparticles (AuNPs) in forming efficient drug or gene delivery vehicles is 
of great importance, with research ongoing into methods to improve the bio-stability, 
biocompatibility and water solubility of AuNPs. Studies have shown that the addition of polymers 
to the surface of gold nanoparticles has resulted in greater stability. It has further been reported111 
that by replacing the surfactant bilayer using thiol-terminated methoxypoly (ethylene glycol) on 
gold nanorods allowed for the successful conjugation of anti-rabbit IgG.  
Cationic polymers can serve as both a stabilizing agent and a cross linker in attaching therapeutic 
agents. The use of such cationic polymers has been shown to prevent the aggregation of gold 
nanoparticles, which is vital when the nanoparticles are exposed to an environment of high ionic 
strength. These cationic polymers have the added advantage of improving the cellular uptake of 
nanocomplexes, and increasing the overall circulation time of the nanocomposites in vivo112, 113. 
There are several strategies which can be employed to modify the surface of AuNPs, and can 
essentially be divided into covalent and non-covalent methods. 
Covalent interactions of polymers with the surface of AuNPs will produce stronger bonds, which 
could be a disadvantage in some instances. If the therapeutic agent is bound too strongly to the 
surface of the nanoparticle, there may be issues associated with the efficient release of the agent 




abundance of positive charges on their surface, through ionic interactions with ligands containing 
amine or acidic groups115. Functionalization of AuNPs with cationic polymers results in the 
formation of delivery vehicles which show a greater level of biocompatibility, lower toxicity and 
the ability to increase the load of therapeutic agents116. Two polymers which have gained much 
attention in recent years, viz. chitosan (CS) and poly-l-lysine (PLL), are attractive alternatives to 
both sterically stabilize nanoparticles and serve as cross linkers, allowing for many anionic 
therapeutic agents to be functionalized to the surface of gold nanoparticles.  These polymers are 
not affected by the presence of electrolytes, therefore allowing for a more permanent method of 
stabilization. These two polymers that are utilized in this study are discussed below117. 
 
2.11.1 Chitosan (CS)        
Chitosan is a naturally occurring carbohydrate polymer, which is obtained from the deacetylation 
of chitin (Figure 2.3). Chitin is primarily sourced from the exoskeleton of marine animals such as 
crabs and shrimps118. Similar in its structure to the polysaccharide cellulose, chitosan is also 
composed of a linear β-(14) linked monosaccharides. The difference in their structure is that 
chitosan contains 2-amino-2-deoxy-β-D-glucan residues, joined through glycosidic linkages. 
Resulting primary amine group, is what imparts the unique properties possessed by chitosan, 
making them desirable for biomedical applications. 
 
 





Briefly, chitosan is synthesized through hydrolysis of the aminoacetyl groups of chitin in an 
aqueous alkaline solution. Chitosan presents with many desirable characteristics, which make it 
suitable for biological applications. Studies have shown that chitosan entraps bioactive molecules 
through several mechanisms viz. ionic crosslinking, chemical crosslinking and through ionic 
complexation. In addition, chemical modification of chitosan has been of great benefit in 
improving the association of bioactive molecules to polymers, whilst also generating a controlled 
drug release profile. Chitosan has been utilized in other delivery systems, including liposomes as 
a coating agent, due to their high affinity for the cell membrane, studies have concluded these 
characteristics of chitosan and their derivatives show promise as materials to form part of 
controlled drug and gene delivery systems120, 121. The functional groups present in chitosan, allows 
for simple conjugation of targeting ligands and therapeutic agents. Due to chitosan’s high level of 
biocompatibility, it does not trigger allergic reactions. It is biodegradable and slowly degrades into 
harmless products including amino sugars, which are absorbed by the human body122. Other 
desirable characteristics include ,  presence of positive charges, mucoadhesive properties123, low 
toxicity124, 125, and high levels of adhesion and immunostimulating properties126. One of the 
limitations of chitosan is its insolubility at physiological pH due to its cationic nature, however 
due to the numerous advantageous properties they possess, many chitosan derivatives have been 
synthesized, with the aim if making them more compatible for biological applications, many of 
which have been successful127.  
It is important to note that many of the properties of chitosan depend on its molecular weight and 
viscosity128. Research has shown that, higher molecular weight chitosan is more suitable as food 
preservatives than those of lower molecular weight129. Studies have shown that the degree of 
acetylation and the molecular weight have a major influence on the biological and physiological 
properties exhibited by chitosan130, 131. The use of chitosan as an encapsulation or stabilization 
agent is dependent on the pH. At an acidic pH, the primary amine groups present in chitosan 
become protonated, resulting in chitosan being soluble in water. The degree of solubility is reliant 
on the distribution of the free amino and acetyl groups, with good solubility of CS solutions being 
reported in 1-3% acetic acid126.  Chitosan and its derivatives have been studied for their potential 
as non-viral gene delivery vectors132, while chitosan based delivery systems are also under 
investigation for development of gastrointestinal delivery systems133. The positive charge 




as conjugation to gold nanoparticles which present with a slightly negative charge on their surface. 
Interestingly close to physiological pH, the nanocomplex of chitosan and 5-FU will present with a 
positive charge, thus enabling their interaction with the cell membrane which is negatively 
charged, through electrostatic interactions. 
 
2.11.2 Poly-l-lysine (PLL) 
Poly-l-lysine (PLL) is a cationic linear polymer composed of the essential amino acid, lysine. It 
has been shown to interact favorably with cell membranes134, facilitating their uptake. Figure 2.4 
depicts the typical structure of PLL, a positively charged amino acid polymer which contains at 
minimum a single hydrobromide molecule (HBr) per lysine molecule. The presence of the 
hydrobromide, results in PLL occurring in a crystalline state, which assists in its high solubility in 
water.  
 
Figure 2.4 Chemical structure of poly-l-lysine135 
 
Factors such as pH and temperature have been shown to affect the secondary structure of PLL, 
resulting in different conformations such as, random coils, α-helices and β-sheets. At a neutral pH, 
the conformation of PLL is an extended random coil, due to the repulsive forces which exist 
between the protonated amide groups136. These protonated groups are the primary contributing 
factors which allow PLL functionalization of AuNPs.  The active amino groups, which are 
positively charged entities, ensure that PLL interacts readily with cell membranes, assisting in cell 
adhesion 137.  
The functionalization of PLL onto the surface of gold nanoparticles will ensure that many of the 




solubility in water, are conferred to the functionalized molecule138. Functionalization of the AuNPs 
with PLL molecules, occur through interaction of the amino groups on the PLL molecule with 
carboxyl groups present on the surface of gold nanoparticles. The remaining free amino groups 
present on PLL can then serve to act as a cross linker139, allowing for the conjugation of therapeutic 
molecules, eluding to the fact that PLL functionalized gold nanoparticles are promising drug 
delivery carriers.  
 
2.12 Cellular uptake 
Drug delivery systems act through two methods of distribution viz. passive and active targeting 
(Figure 2.5). Passive targeting is dependent on the physiochemical properties of the nanoparticle, 
including size, shape and surface charge of the particle29.  This type of targeting takes advantage 
of characteristics such as leaky tumor vasculature, leading to the enhanced permeability and 
retention (EPR) effect and the tumor microenvironment, which was first reported by Matsumura 
and Maeda21, 25, 140. The nanoparticles can enter the site through passive diffusion or convection141. 
The EPR effect entails two components viz. altered biodistribution and increased plasma half-life 
of the nanocomplexes. The altered biodistribution involves the accumulation of nanocomposites 
at much greater concentrations in the tumor tissue, as opposed to healthy tissue, whilst the 
increased plasma half-life is due to the size of the nanocomposites containing the drug, being 
greater than the renal excretion threshold142.  Passive targeting has the advantage of increasing the 
bioavailability of the drug at the tumor site, because in comparison to the vasculature of healthy 
tissue, tumors are known to present with gaps as large as 800 nm in their angiogenic blood vessels 
and a disorderly structure as seen in Figure 2.6.  
It has been suggested that tumor angiogenic blood vessels are so leaky due to very high levels of 
vascular mediators such as brandykins, vascular endothelial growth factor, prostaglandins and 
nitric oxide to name a few. The combination of such infrastructure and poor lymphatic drainage 
induces the EPR effect143. However, a drawback of this type of targeting may also result in 







Figure 2.6 A scheme depicting drug delivery via active and passive targeting144 
 
 
Figure 2.7: Differences in structure between normal and tumor tissue, assisting in the passive targeting due 
to enhanced permeability and retention effect145.  
 
In comparison, active targeting involves the functionalization of targeting moieties onto the surface 
of nanoparticles. These targeting ligands are selected by determining the type of receptor present 
and upregulated exclusively on specific tumor cells. Active targeting allows for greater 
accumulation of the therapeutic agent at the target site, as the nanoparticles are able to cross 
biological barriers based primarily on molecular recognition146, 147. Studies were carried out by 




and non-specific uptake97. They used gold nanoparticles of varying sizes ranging from 50 nm to 
150 nm, functionalized with and without polyethyleneglycol (PEG5000), and to serve as targeting 
moieties they functionalized galactose residues onto the surface of the gold nanoparticles, for 
targeting asialglycoprotein receptors present on hepatocytes. They found that gold nanoparticles 
of 50 nm were internalized at a faster rate compared to unPEGylated nanoparticles of other sizes.  
 
2.13 Biological barriers to drug delivery in tumors 
The variation in biodistribution of chemotherapeutic drugs when delivered orally has resulted in 
many treatments introducing their drugs intravenously, as a result these drugs circulate the vascular 
system, reaching both healthy and cancerous tissue. Disadvantages of such a delivery method 
include increased cytotoxicity towards healthy tissue, resulting in severe side effects and the 
presence of numerous barriers both intracellular and extracellular before it is able to reach the 
tumor. 
The initial obstacle faced by circulating nanocomposites is the reticuloendothelial system, and 
macrophages which circulate the blood stream148, the sole purpose of which is to rid the body of 
objects not recognized as self.  To avoid such an immune response, the nanocomposites need to 
be coated in a polymer layer which resists binding of proteins referred to as opsonins, via the 
process of opsonization. Opsonins are composed of several proteins including, but not limited to 
fibronectin, type I collagen and immunoglobulins. When the opsonin proteins encounter a foreign 
body, they adhere through a variety of interactions such as electrostatic, ionic and van der waals 
forces. Circulating macrophages identify the opsonin proteins coating the foreign body, followed 
by phagocytosis of the particle149, therefore through the prevention of binding of opsonins, 
particles can circulate for longer in the blood stream. 
Due to the rapid growth of cancerous tissue, tumor vasculature presents with a highly unorganized 
structure, coupled with an absence of smooth muscle resulting in varied blood flow. This poses a 
problem as the therapeutic containing nanocomposite will struggle to disperse through the tumor 
tissue150. Studies have shown that regions of the tumor with limited blood flow prove more resilient 
to the effects of chemotherapeutic agents151.  
The area within the tumor, referred to as the interstitium contains a combination of collagen and a 




contained towards the center. This buildup in pressure can be attributed to a number of factors 
including lack of lymphatic drainage and rapid cellular proliferation in a confined area153. Due to 
the increase in pressure, drug containing nanocomposites will find it difficult to penetrate deep 
into the tumor mass152. 
The exact mechanism by which nanoparticles are eventually removed from the body, is not fully 
understood, and requires further investigation. However, due to nanoparticles circulating the 
vascular system, it is thought that they accumulate in the spleen or are entrapped by 
macrophages154. The mechanism by which nanoparticles are taken into the cell, is also not fully 
understood, but an understanding of basic cellular uptake mechanisms eludes to endocytosis as 
being the main pathway. Phagocytosis usually involves the uptake of particles greater than 500 
nm. However, most synthesized inorganic molecules fall within the range of 1-100 nm, and even 
with surface modifications they are unlikely to be in the range of 500 nm. It has been shown that 
when gold nanoparticles are incubated with cell culture media, serum proteins form an 
encapsulating layer around the nanoparticle. It is suggested that this layer is beneficial in the uptake 
of nanoparticles into cells155. These types of interactions could prove vital in understanding cellular 
uptake mechanisms better, facilitating the need for more research to be conducted in this area. 
 
2.13   Intracellular Trafficking of nanoparticles  
The mechanisms by which nanocomplexes are internalized into cells are not yet properly 
understood, however their entry from the extracellular space may occur via the main pathways 
such as nonspecific uptake, micropinocytosis or clathrin-coated pits capable of internalizing 
nanoparticles ranging from 10 to 300 nm156 (Figure 2.7).  Such pathways are known to transport 
particles into the cell, eventually leading to early endosomes. Alternatively, some nanocomposites 
may be transported via the endoplasmic reticulum or the golgi body, or from the early endosomes 
towards the lysosomes, often leading to their degradation. The preparation of most colloidal 
solutions often does not result in even size distribution. This factor could greatly influence the 
uptake of nanocomplexes into the cell, as size is related to their specific physiochemical properties. 
The obvious limiting factor in successfully delivering therapeutic agents into cells, is their cellular 
uptake. One can argue that for every delivery vehicle, there will be an ‘optimum’ size limit which 




that the low volumes of therapeutic agents reaching the desired cells are due to the inability of the 
delivery vector to escape the endosomal compartments, thus gaining entry into the cytoplasm. 
Therefore, many agents such as fusogenic peptides, which can disrupt the endosome have been 
suggested to be incorporated into the delivery systems. These peptides exist in a random coil 
conformation, however under the appropriate conditions, they can form an amphiphilic α-helical 












Figure 2.8 Possible endocytosis pathways for cellular uptake of nanocomplexes157  
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Gold nanoparticles (AuNPs) have emerged as potential vehicles for drug delivery due to their 
favorable attributes such as their apparent low toxicity, high surface area, optical properties, 
biocompatibility, high loading capacity, ease of synthesis and modification. Most anticancer drugs 
available do provide some benefit but are rapidly metabolized in the body after administration, 
reducing their effectiveness. In addition, many of them produce unpleasant and severe side effects. 
Hence, there is a need for a safe and effective drug delivery system that will ensure sustained and 
controlled drug release to the desired tumor site. In this study, AuNPs were chemically synthesized 
and functionalized using two different methods, with the cationic polymer chitosan for delivery of 
the anticancer drug 5-fluorouracil (5-FU). All nanoparticles and their nano-complexes were fully 
characterized using UV-vis spectroscopy, ICP, FTIR, TEM and Nanoparticle Tracking Analysis 
(NTA).   
The methods of encapsulation and linear binding of the polymer to the AuNPs were investigated 
and revealed that the encapsulation method had a superior drug binding efficiency compared to 
the linear method. Drug release studies over a 7-hour period showed that there was a steady and 
controlled release of the drug. In vitro cytotoxicity assays, using the MTT and SRB assays were 
carried out on three human cancer cell lines, viz. Caco-2 (colon adenocarcinoma), HEPG2 
(hepatocellular carcinoma), MCF-7 (breast adenocarcinoma) and a non-cancer cell line, HEK293 
(embryonic kidney).  This study, displayed a clear specificity of the nanocomplexes towards the 
cancer cell lines with little or no significant toxicity observed in the non-cancer cell line. This 
highlights the immense potential of these cationic polymer functionalized AuNPs in providing safe 
and efficient drug delivery with limited side effects.  











Cancer is one of the leading causes of mortality in the Unites States, with more than ten million 
individuals diagnosed each year. Even developing countries, including South Africa have seen an 
unprecedented increase in cancer cases and mortality in recent years. The mechanism through 
which cancer develops is thought to be a complex, multistep process, involving a number of 
cellular physiological systems and genetic alterations, including cell signaling pathways, 
replication and apoptosis 1, 2. This intricacy and heterogeneity encourages the aggressive growth 
of cancerous cells resulting in significant morbidity and mortality in patients3, 4. In the United 
States, colon cancer represents approximately forty percent of all cases diagnosed annually and is 
the third leading cause of death in males and the fourth leading cause in females 5-9.  
Cancer begins as a growth localized to an organ or tissue in the body, and progresses to form 
clumps of cells that can detach and migrate to distant organs or tissues via the vascular or lymphatic 
systems, a process termed metastasis. At this stage the treatment of the disease becomes more 
complex and poses various additional obstacles10. With regard to colon cancer, colonic adenomas 
undergo conversion to colonic cancer over an extended period time 11. Initially the mass develops 
as a soft polypoid tumor, growing in the direction of the lumen of the colon, leading to ulceration 
and hemorrhage12. Current methods of treatment are dependent on the outcomes of clinical and 
pathological staging, determined through morphologic diagnostic tools, including radiological and 
histopathological examinations. Common cancer treatment regimens include surgical resection of 
the tumor followed by either radiation or chemotherapy or a tailored combination of both10, 13. 
Notwithstanding the numerous advances in these conventional methods of treatment, cancer 
treatment options are not optimal.  
Conventional methods of treatment possess their own limitations including nonspecific 
distribution of anticancer agents, resulting in the destruction of both healthy and cancerous tissue, 
multiple drug resistance and below optimal concentrations of anticancer complexes at the site of 
action 3, 14, 15. In view of the above impediments, the key to successful cancer treatment lies in the 
delivery of anticancer complexes, at optimum concentrations to the site of tumor formation, thus 
targeting the activity of the drug towards cancerous tissue and minimizing its effect on normal 
healthy tissue. Nanotechnology, a multidisciplinary science, is seen as an important technology by 




years, the field of nanotechnology has been progressing rapidly. According to the metric scale, a 
nanometer is in reference to the size of an object being one billionth of a meter. The term of 
nanotechnology was first coined by Norio Taniguchi17 in 1974, and was said to involve the 
processing, separation, deformation and synthesis of new materials by one atom or molecule18.  
Progress in the field of nanotechnology has resulted in an increase in its applications in medicine 
and industry. Nanoparticle size is key to understanding the applications it is best suited towards. 
In the medical field, nanotechnology is applied in the synthesis of vectors and therapeutic 
diagnostic tools, to enhance imaging, sensing19, and for targeted drug and gene delivery20, 21. 
Nanotechnology has resulted in an improvement in the sensitivity of established techniques, 
leading to a lowering of the risks of cytotoxicity towards healthy tissue, commonly associated with 
conventional radiation and chemotherapy. Nanoparticles themselves are fast becoming powerful 
tools in the fight against serious conditions such as cancer 22. 
 When nanotechnology is used in the diagnosis, treatment and control of various conditions, it is 
termed nanomedicine. Nanomedicine, although a relatively new field, can be dated back decades 
to the first recorded use in medicine of lipid vesicles (later called liposomes) in 1965 23, and 
quantum dot bio conjugates in 199424, 25. Quantum dots fluoresce under exposure to UV light, and 
when injected can easily enter cancerous tissue, allowing visualization of the tumor during 
procedures such as magnetic resonance imaging (MRI)26. As research in this area advances, it is 
becoming clear that nanoparticles offer unique properties which include but not limited to, 
enhanced permeability and greater retention times. Thus, the prevalence of nanotechnology in the 
medical field is increasing.  
The size of nanoparticles ensures that they are more readily taken up by cells when used as 
nanovectors for gene delivery 27. Furthermore, nanoparticles possess a functional surface, that 
allow for the binding and adsorption of a variety of compounds, making them suitable drug 
delivery vehicles28-30. This nanocomplex formation affords protection to the drug from degradation 
in vivo, improves bioavailability and enables the prolonged release of the anticancer agent31. 
Among the various nanoparticles under study today, noble metal nanoparticles show great promise 
due to their unique optical properties32, non-toxicity and high levels of biocompatibility33, and in 
the case of the gold nanoparticles (AuNP’s) the relatively inert core34. In addition, AuNP’s with 




the advantage of cheap and ease of synthesis. The ability of  AuNP’s to successfully convert light 
or radio frequency into heat36, has been exploited for the thermal destruction of targeted cancer 
cells. These properties allow for tailored treatment options in cancer therapy, such as treatment of 
cancerous cells using drugs such as 5-Fluorouracil, together with photothermal therapy. Such 
applications could improve the recovery rates in colorectal and associated cancers.  
Nanoparticles boast a high surface to volume ratio, allowing for increased loading of targeting and 
therapeutic materials37. However, one of the major obstacles faced by researchers, is the tendency 
of gold nanoparticles to agglomerate during reduction from its metal salts. It is important to control 
the size of AuNPs, since an increase in size of nanoparticles have shown limitations in their use as 
drug delivery vectors 38, where particles with sizes ranging from 10 to 100 nm were most effective 
in the treatment of cancer and related diseases. Nanoparticles within this size range are readily 
taken up by cells. Hence, there is a need to prevent the agglomeration of gold nanoparticles, 
possibly by the use of a stabilizing agent 39-41.  
Cationic polymers such as chitosan are popular, and have been used as stabilizing agents, mainly 
due to their high biocompatibility, biodegradability, non-toxicity, and the added advantage of 
containing NH2 and OH groups which allow for the binding of drugs and other molecules 
42-45. The 
combination of chitosan and nanoparticles in the form of nanocomplex matrices provide a larger 
surface area, allowing higher concentrations of drugs to be loaded onto the nanocomposite. These 
matrices also generate an environment which is conducive to long term stability for use as a drug  
delivery vector 46.  
Of the various anticancer agents available presently, 5-Fluorouracil (5-FU) was selected. It is a 
broad spectrum anticancer agent, which can be used alone or in combination with other drugs in 
chemotherapy. Whilst this drug has shown to be very effective in eliminating cancerous tissue, it 
shows no specificity. It exhibits high levels of cytotoxicity, therefore destroying healthy tissue in 
the process, limiting its use in the treatment of cancer47. The aim of introducing gold nanoparticles 
is to bring about a reduction in the cytotoxic effects towards non-cancerous tissue and an overall 
increase in anticancer activity in cancerous tissue.  
To the best of our knowledge, there is very limited research which has been published on the 
cytotoxic effects of 5-FU loaded chitosan conjugated gold nanoparticle (CS-AuNP) 




lines. This study involves investigation of the encapsulation and linear binding methods of 5-FU 
onto CS-AuNP nanocomposites, to determine, which method offers greater biocompatibility, and 
efficiency in delivery of the drug in vitro. Furthermore, their respective drug release profiles and 
anticancer activities were examined, noting dose dependency and cell specificity.  
 
3.2 Materials  
Gold (III) chloride trihydrate (Mw: 393.83 g mol
-1, HAuCl4.3H2O), chitosan ≥ 75% deacetylated   
(Mw: 1000-5000), Polysorbate 80 (Tween 80, Mw: 1,310 g mol
-1, C64H124O26), Sodium 
triphosphate (Mw: 367.86 g mol-1, Na5P3O10) 5-Fluorouracil (Mw: 130.1 g mol
-1, C4H3FN2O2), 
Sulforodhamine B (SRB Dye, Mw: 558.67 g mol-1, C27H30N2O7S2), Acridine Orange hemi (zinc 
chloride) salt [3,6-Bis(dimethylamino) acridine hydrochloride zinc chloride double salt] (Mw: 
265.36, g mol-1, C17H19N3), and dialysis Tubing (MWCO= 1000 Daltons) were supplied by Sigma-
Aldrich Chemical Co., (St. Louis, USA). Sodium citrate tribasic dehydrate, phosphate-buffered 
saline tablets [PBS, (140mM NaCl, 10mM phosphate buffer, 3mM KCl)], 3-[(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), ethidium bromide, glacial acetic acid, and 
dimethyl sulfoxide [DMSO], were supplied by Merck (Darmstadt, Germany). The human cells, 
embryonic kidney (HEK293), colorectal adenocarcinoma (Caco-2), hepatocellular carcinoma 
(HepG2) and breast adenocarcinoma (MCF-7) were obtained from the American type culture 
collection (Pty) Ltd, Manassas, Virginia, USA. Sterile Fetal Bovine Serum (FBS) was supplied by 
Hyclone GE Healthcare (Utah, USA). Eagle’s Minimum Essential Medium (EMEM) with L-
glutamine (4.5 g ml-1), Penicillin/ Streptomycin/ Amphotericin B (100x) antibiotic mixture 
[Amphotericin B (25 mcg ml-1), NaCl (8.5 mg L-1) Potassium penicillin (10 000 Units mL-1), 
Streptomycin sulphate (10 000 mcg ml-1)] and trypsin-versene-EDTA mixture [versene-EDTA 
(200 mg L-1), Trypsin (170 000 U L-1)] were supplied by Lonza Bio Whittaker (Verviers, 
Belgium). All sterile tissue culture plasticware were obtained from Corning Inc., (New York, 
USA). All other reagents were of analytical grade and ultrapure (18 MOhm) water (Milli-Q 







3.3.1 Preparation of colloidal gold nanoparticles (AuNPs) 
AuNPs were chemically synthesized using an adaptation of the Turkevich method, involving the 
chemical reduction of Gold (III) chloride trihydrate (H[AuCl4]) with sodium citrate (NaC6H5O7). 
Briefly, 25 ml of 18 MOhm water in a round bottom flask was heated under constant stirring to a 
temperature of 85-95 ˚C. To this was added 375 µl of a 3 x 10-2 M of H(AuCl4) solution, followed 
by the addition of 1 ml of 1% sodium citrate, directly into the vortex of the solution. An immediate 
a color change from a pale yellow to dark blue after 5 minutes and finally to a deep wine red after 
15 minutes of constant heating and stirring was observed. Solution was stirred for a further 5 
minutes, thereafter cooled to room temperature and stored in a dark bottle at room temperature. 
The final concentration of the aqueous colloidal AuNPs was 0.45 x 10-3 M. The conjugation of 
chitosan and 5-FU was achieved using two different methods as outlined in 3.3.2 and 3.3.3. 
 
3.3.2         Synthesis of 5-FU encapsulated CS-AuNP nanocomplex 
Approximately, 2.5 ml of 5-FU solution (3.8 mM in 18 MOhm water) was added to 2.5 ml of 
chitosan solution (0.75 mg ml-1 in 2% acetic acid) with constant mixing. Thereafter, Tween 80 
(0.5% v/v) was added, and pH maintained between 4.6-4.8. Sodium tripolyphosphate (TPP) (1.25 
ml) was then added to obtain a Chitosan: TPP ratio of (2:1 v/v). After gentle stirring for 180 
minutes, to ensure adequate adsorption of 5-FU onto the nanoparticles, 2 ml of colloidal AuNP 
solution (0.45 x 10-3 M), was added dropwise to 2 ml of 5-FU/Chitosan nanoparticles under gentle 
constant stirring.    
 
3.3.3      Linear Synthesis of 5-FU:CS-AuNP nanocomplex  
Approximately, 2.5 ml of 5-FU solution (3.8 mM) was added to 2.5 ml of chitosan (0.75 mg ml-1 
in 2% acetic acid). After gently stirring for 180 minutes, 2 ml of colloidal AuNP solution (0.45 x 
10-3 M) was added dropwise to 2 ml of the 5-FU/ CS solution under gentle constant stirring for a 






3.3.4     UV-vis spectrophotometry analysis 
UV-vis spectrophotometric analysis was conducted on colloidal solutions of all synthesized 
nanoparticles and noncomplexes to determine their absorption spectra, allowing for the correlation 
of the data with that of literature, thereby confirming their successful synthesis. The expected 
surface plasmon resonance (SPR) absorption of the gold nanoparticles is at 520 nm, with any shift 
in the absorption spectra indicating successful conjugation of the polymer and/or drug. Solutions 
were measured using a Biomate 3 spectrophotometer (Thermo Fischer Scientific Inc., Waltham, 
Massachusetts, USA).  All samples were sonicated and vortexed prior to analysis to ensure 
uniformity of the solution. 
 
3.3.5     Transmission Electron Microscopy (TEM) 
To determine the size and ultrastructural morphology of all nanoparticles, TEM studies were 
conducted. Approximately, 10 µl of the respective nanoparticle/ nanocomplex samples was placed 
onto a 400-mesh carbon coated copper grid (Ted Pella Inc. Redding, USA), and allowed to air dry 
at room temperature for 1 hour. Thereafter, samples were viewed at 60 000x magnification using 
a JEOL-JEM T1010 (Jeol, Tokyo, Japan) electron microscope without warming above -150C, at 
an acceleration voltage of 100 kV. Images were captured using the iTEM Soft Imaging Systems 
(SIS) Megaview III fitted with a side-mounted 3-megapixel digital camera. 
 
3.3.6 Nanoparticle Tracking Analysis (NTA) 
For accurate representation of size distribution and zeta potential of all nanoparticles and 
nanocomplexes, analysis was performed using NTA (Nanosight NS-500, Malvern Instruments, 
UK) at 25C. Approximately, 1 ml of a 1:500 dilutions (in 18 MOhm water) of each sample was 
evaluated. The instrument was first primed and flushed, and the zero position on the camera set. 
All samples were run in triplicate.             
 
3.3.7     Inductively coupled plasma-optical emission spectroscopy analysis (ICP) 
Quantification and elemental detection of the Au concentration present in the colloidal AuNP 




OES). This was performed on a Perkin Elmer optima 5300 DV optical emission spectrometer. A 
standard curve between 1 – 20 ppm, was set up from an Au standard stock solution of 100 ppm.  
 
 3.3.8     Fourier transform infra-red analysis (FTIR) 
FTIR was employed to confirm the presence of essential groups and bonds in the nanoparticles, 
through visualization of the presence of specific peaks. The spectrum was run using 200 µl of the 
respective sample in a Spectrum Perkin Elmer spectrophotometer, and the respective IR spectra 
were obtained using Spectrum Analysis Software. 
 
3.3.9     Encapsulation efficiency  
Approximately, 2 ml of each nanocomplex (encapsulated and linear) were dialyzed (MWCO=1000 
Da), against 15 ml PBS for 12 hours at 37˚ C. Initial absorbance readings pre-dialysis, for each 
nanocomplex (1 ml) were obtained at 266 nm. Following the 12-hour incubation, 1 mL of each 
dialyzed sample was analyzed, and reading taken as the total bound 5-FU. The following equation 
was used to determine the encapsulation efficiency of 5-FU:                                       
Encapsulation efficiency (%) = (Total 5-FU)- (Bound 5-FU)/ (Total 5-FU) x 100  
 
 
3.3.10     Drug release studies 
To determine the controlled ability of the nanocomplexes to release 5-FU over a period of time, 
and at pH 4 and pH 7, drug release studies were performed. Approximately, 2 mL of each 
nanocomplex (encapsulated and linear) were dialyzed (MWCO= 1000 Da) against PBS (5 ml) for 
12 hours at 37˚C. At hourly intervals, a 2 µl sample was removed and analyzed on a Nanodrop 
oneC, UV-vis spectrophotometer (Thermo-Fischer Scientific Inc., Waltham, Massachusetts, USA) 
at 266 nm. These readings were used to generate a drug release profile for the respective 
nanocomplexes under the different pH conditions. 
 
3.3.11      Reconstitution, propagation and maintenance of cell lines in vitro   
All tissue culture related studies were conducted under sterile conditions in an Airvolution Class 




centrifuged at 3000 rpm for 60 seconds. The cell pellet was re-suspended in 1 ml of complete 
medium (EMEM containing 10% (v/v) FBS and antibiotics (100 U ml
-1 penicillin, 100 µg ml-1 
streptomycin), warmed to 37˚C. Cells were then propagated and maintained in 25 cm2 tissue 
culture flasks containing 5 ml of medium, at 37˚C in a HEPA class 100 Steri-Cult CO2 incubator 
(Thermo-Fisher Corporation, Waltham, Massachusetts, USA). The medium of reconstituted cells 
was changed after 24 hours to remove any traces of the cryopreservatant. The growth of cells was 
monitored daily under a Nikon TMS inverted microscope (Nikon Corp, Tokyo, Japan). Depending 
on the growth of cells, spent medium was replenished, cells subcultured for propagation or cell 
culture assays or cells were cryopreserved.  
 
3.3.12     Trypsinization  
Medium and cell culture reagents were first warmed to 37˚C in a water bath. Cells were washed 
with 5 ml of PBS (pH of 7.5), and 1 ml of trypsin-versene was added to cells. Trypsinization was 
carried out at 37˚C, with constant monitoring under an inverted microscope. Trypsinization 
involves the action of the proteolytic enzyme trypsin, which catalyzes the degradation of cellular 
proteins which allow the cells to attach to culture flasks.  Once cells were seen to be “rounding 
off”, trypsinization was stopped by the addition of 1 ml of complete medium containing serum that 
inhibits the action of the enzyme. The flask was then gently tapped against the palm of the hand to 
dislodge all the cells. Cells were then split into separate culture flasks, multiwell plates or 
alternatively cryopreserved.  
 
3.3.13     Cryopreservation  
Following trypsinization cells were centrifuged at 3000 rpm for 1 minute. Pelleted cells were then 
re-suspended in a solution containing 0.9 ml of complete medium and 0.1 ml of DMSO 
cryopreservation medium), mixed by vortexing and dispensed into sterile 2 ml cryogenic vials. 
The vials were placed into a NalgeneTM “Mr Frosty” Cryo 1˚C freezing container, containing 
isopropanol. Cells were frozen at a rate of -1 ˚C per minute to a final temperature of -70 ˚C, and 
then stored in a -80 ˚C biofreezer (Nuaire, Lasec Laboratory and Scientific equipment), for short 





3.3.14      MTT cytotoxicity assay 
Confluent cells were trypsinized and seeded into clear 96- well plates at seeding densities between 
2.4 x 104 - 2.9 x 104 cells per well, and incubated at 37˚C for 24 hours to allow for attachment of 
cells. Thereafter, spent medium was replaced with 200 µl of fresh medium, followed by addition 
of the respective nanoparticles (AuNP’s, Au-CS, Au-CS:5-FU Encapsulated, Au-CS:5-FU Linear 
and CS:5-FU) at different concentrations as set out in Table 3.1. Positive controls containing cells 
only, were included and recorded as 100 % survival. Assays were conducted in triplicate. Cells 
were incubated for 48 hours at 37˚C in 5% CO2. Thereafter, the medium was removed and replaced 
with 100 µl fresh medium and 100 µl of MTT reagent (5 mg/ml in PBS), and cells incubated for 4 
hours at 37 ˚C. The medium containing MTT was then removed, and 200 µl of DMSO was added 
to each well, to solubilize the insoluble formazan crystals. The absorbance was then read on a 
Mindray MR-96A microplate reader (Vacutec, Hamburg, Germany) at 570 nm, using DMSO as a 
blank. The cell viability (%) was calculated using the following equation:  
(Abs of treated – Abs of control/ Abs of control) x 100%. 
 
Table 3.1.    Ratios of respective nanoparticles and nanocomposites used in cytotoxicity assays 











 1:0 1:1 2:1:1 2:1:1 1:1 1:1 
1 0.134 µg 3.88 µg 0.275 µg 0.275 µg 1.866 µg 1.555 µg 
2 0.268 µg 7.77 µg 0.549 µg 0.549 µg 3.732 µg 3.110 µg 
3 0.402 µg 11.7 µg 0.884 µg 0.884 µg 5.598 µg 4.665 µg 
4 0.536 µg 15.5 µg 1.090 µg 1.090 µg 7.464 µg 6.221 µg 
 
 
3.3.15     SRB cytotoxicity assay 
This assay was set up as for the MTT assay (3.3.14, Table 3.1). After the 48-hour incubation, 50 
µl of TCA (50%) was gently layered onto the cells, taking care not to dislodge cells. The plates 
were then incubated for 1 hour at 4˚C, followed by washing (3x) with 18 MOhm water, to remove 
excess serum and fixative agent. Plates were then dried at 40˚C for 1 hour, followed by the addition 




the dark at room temperature. Excess dye was removed by washing (3x) with 1% acetic acid. The 
protein bound dye was solubilized with 200 µl of 10 mM Tris base, and plates read on a Mindray 
MR-96A microplate reader at 565 nm using Tris base as the blank.  Cell viability was calculated 
is in 3.3.14. 
 
3.3.16     Mechanism of cell death - Apoptosis Assay 
This assay is a rapid fluorescent technique for the detection of cell apoptosis in vitro, and uses the 
dual dye system of acridine orange and ethidium bromide. The dyes were each prepared to a 
concentration of 100 mg.ml-1 in PBS and mixed at a ratio of 1:1, prior to the start of the assay. 
Cells were seeded into clear 24-well plates at a density of 1.2 x 105 cells per well, and incubated 
at 37˚C for 24 hours. Spent medium was then replenished with 400 µl of fresh medium and 
respective nanoparticles (Au-CS:5-FU encapsulated and Au-CS:5-FU linear) were added at a mass 
of 0.917 µg and 0.983 µg. Positive controls containing untreated cells were used. Assay was done 
in triplicate. Cells were incubated for 48 hours at 37˚C in 5% CO2, thereafter washed with 100 µl 
of cold PBS, followed by the addition of 15 µl of the dye solution to each well. Cells were viewed 
under an Olympus fluorescent microscope (200x magnification), fitted with a CC12 fluorescent 
camera (Olympus Co., Tokyo, Japan). The apoptotic indices were calculated according to the 
following equation:  
Apoptotic Index = Number of Apoptotic cells/ total number of cells counted.   
 
3.3.17     Statistical analysis 
All data has been presented as mean ± standard deviation (± SD n=3). The Dunnetts post hoc test 
was used for the MTT and SRB assay. Statistical significance of the tests was set at **p<0.01 and 
*<0.05. Each of the experimental values were compared to their corresponding control. The 








3.4     Results and discussion 
 
3.4.1  UV-vis studies 
The UV-vis spectra obtained for the AuNP’s, Au-CS, Au-CS:5-FU encapsulated and Au-CS:5-FU 
linear bound nanocomplexes are shown in Figure 3.1. The AuNP’s exhibited a single narrow peak 
absorbance band at 522 nm, which corresponded to the surface plasmon excitation of small 
spherical monodispersed and well-separated AuNPs, that peak in the 522-525 nm range48. The 
presence of a single visible peak, indicates that there were very low levels of by-product present 
from the sodium citrate reduction reaction, as excess citrate and its oxidation products would 
appear as a separate peak if they were present in large volumes. For Au-CS a single peak at 524 
nm was observed, indicating a shift in SPR due to the polymer conjugation.  For Au-CS:5-FU 
encapsulated and Au-CS:5-FU linear, there were single peaks visible at 528 nm and 530 nm 
respectively, due to successful conjugation of Au-CS to 5-FU. There was a decrease in the overall 
absorbance of the nanocomplexes when compared to the colloidal gold nanoparticles, indicating 
that the nanoparticles are small in size, since smaller nanoparticles possess a reduced mean free 
path for the electrons, leading to a less pronounced peak. It also suggests that there was a lower 










3.4.2 ICP-OES and FTIR analysis 
The ICP analysis performed was able to confirm the concentration of the synthesized AuNP.  
Characterization using FTIR, further confirmed that successful conjugation of the polymers to 
the AuNPs. The FTIR spectrum of Au-CS are shown in Appendix A. The FTIR spectrum of 
nanocomposites containing chitosan presented with a peak due to N-H, O-H stretching at ~ 3254 
cm-1, a peak due to NH3
+ ~ 1508 cm-1 and C-O stretching at ~ 1028. These peaks correspond 
well to that of pure chitosan as seen in literature.    
 
3.4.3 TEM  
The TEM images of the nanoparticles and nanocomplexes are shown in Figure 3.2 (A-D).              





















light background, which is due to the noble metal which has a dense core and therefore reflects the 
beam of electrons from the TEM.  Furthermore, the particles were polydispersed, with very little 
large scale agglomeration. These results were further supported by the UV-vis studies, which 
indicated that the colloidal solution consisted of nanoparticles which were small in size, less than 
100 nm in diameter. For Au-CS (Figure 3.2 B), a layer of chitosan can be vaguely seen in the 
background surrounding each AuNP. This supports the UV studies, that the binding of chitosan to 
AuNP was successful. The molecules show a small level of aggregation; which is to be expected. 
The Au-CS:5-FU encapsulated nanocomplexes (Figure 3.2C) appear to be slightly smaller in size 
than the Au-CS:5-FU linear nanocomplexes (Figure 3.2D). This was confirmed from the NTA 
analysis (3.4.4.). The nanocomplexes however show a greater level of dispersion, indicating 
colloidal stability and the potential to function better in the delivery of the drug to cancer cells due 










Figure 3.2    TEM imaging of (A) Au nanoparticles, (B) Au-Chitosan, (C) encapsulated Au-Chitosan:5FU 
                      (D) linear Au-Chitosan:5-FU. Bar = 50 nm. 
 
3.4.4 Nanoparticle Tracking Analysis (NTA)  
NTA was used to accurately determine nanoparticle and nanocomplex size distribution, colloidal 
stability and zeta potential, as shown in Table 3.2. The results indicate that the AuNP’s had a mean 




nanoparticles under 100 nm. Zeta potential is the surface charge in a particular solvent with a 
specific ionic strength, and is a measure of the repulsive forces which are present. A large zeta 
potential value either positive or negative is a good indicator of long term colloidal stability. The 
AuNP’s had a low zeta potential value of -7.3 mV, which increased to +55 for CS-Au, which 
suggests that these nanoparticles had good colloidal stability. Furthermore, it is an indication of 
the strength of the bond between chitosan and AuNP. A shift from an overall negative charge for 
the AuNPs to large positive zeta potential values in the case of the nanocomplexes is an indication 
of the successful and strong association between the respective polymers and the surface of the 
gold nanoparticle. This correlates with the results obtained from the UV-vis and TEM studies. 
Furthermore, the increase in sizes seen in CS nanocomplexes can be attributed to the binding of 
chitosan, which interacts efficiently with the gold surface. Upon addition of the anionic drug, 5-
FU to the CS-AuNP, there was an increase in the size of each nanocomplex, encapsulated and 
linear, from 69.6 nm to 90.4 nm and 95.3 nm, respectively. This also confirms that the higher 
positive zeta potential value of CS-AuNP:5-FU linear allowed for a stronger, more stable 
interaction between chitosan and the drug. Furthermore, as evidenced from EM studies the linear 
method produced slightly larger nanocomplexes than with the encapsulation method (95.3 nm vs 
90.4 nm). 
 
           Table 3.2. Size distribution and Zeta potential analysis of AuNP and its nanocomplexes. 
Sample Nanoparticle size (nm) Zeta potential (mV) 
AuNP              65.9        9.8 -7.3         1.6 
AuNP-CS              69.6        15.2 +55         1.2 
AuNP-CS:5-FU Encap              90.4        1.5 +8.3        1.3 
AuNP-CS:5-FU Linear              95.3        12.2 +27.2      1.5 
 
3.4.5 Encapsulation efficiency  
The encapsulation efficiency was determined through UV-vis spectrometry, from the absorption 
spectra of nanocomplexes containing 5-FU before and after dialysis.  The amount of free drug was 
calculated from the absorption measurements, which was in turn used to calculate the amount of 




was calculated to be 89.95%, whilst the binding efficiency of Au-CS:5-FU using the linear method 
was found to be 72.45 %. This confirms that the encapsulation method was superior to the linear 
method in the binding of 5-FU. Nevertheless, a binding efficiency of 72.45 % achieved using the 
linear method still provided a relatively high level of entrapment of 5-FU into the nanocomplex.    
 
3.4.6 Drug release studies 
Cancerous cells have a lower pH value, compared to normal tissue49. It has been reported 50 that 
5-FU is released quickly and continuously at a pH value around 5, due to the gel-sol transition that 
takes place, releasing 5-FU. A drug release analysis was done spectrophotometrically at pH 7 and 
4, and measured at 266 nm since 5-FU peaks between 266 - 271 nm. The results (Figure 3.3) show 
that at pH 7.0, the linear bound nanocomposite, released the drug at a quicker rate and in higher 
volumes compared to the encapsulated nanocomposite. Release of the drug in high volumes under 
neutral pH, may result in non-specific cytotoxic effects towards healthy tissue or the expelling of 
the drug from the body before any therapeutic effect may occur, which can be avoided by the 
encapsulation method. At pH 4.0, both nanocomposites released the drug, however a more 
controlled release was seen for the encapsulated nanocomposite, compared to the linear bound 
nanocomposite, indicating the effective release of the drug under acidic conditions, which is highly 
favourable due to biology of cancerous cells. The encapsulated nanocomposite was shown to be 
more effective at binding the drug in higher volumes and releasing the drug in a controlled manner 
under appropriate conditions. Approximately, 30% and 41% of the drug was released from 
encapsulated and linear bound nanocomplexes respectively at a pH of 4.0. Hence, whilst both 
nanocomposites are capable of sustained release of the drug over a period of time, the encapsulated 





Figure 3.3   Drug release profile of 5-FU from nanocomplexes in the encapsulated and linear method at  
                    pH 4.0 and 7.0 
 
 
3.4.7  In vitro Cytotoxicity analysis 
3.4.7.1  MTT Assay 
The cytotoxicity of the respective nanocomplexes was investigated using the MTT assay, a 
quantitative colorimetric assay, relying on the premise that viable cells retain their mitochondrial 
enzyme activity and reduce the tetrazolium salt into intensely colored insoluble formazan products. 
One of the attractive features of using gold as a delivery vehicle is that due to its chemically inert 
core, it is essentially non-toxic to cells51. The toxicity profile of AuNP and its nanocomplexes at 
selected ratios (Table 3.1) were evaluated in the four human cell lines viz. HepG2, HEK293, Caco-
2 and MCF-7. The amount of 5-FU used as controls were determined from the concentration of 5-
FU present in the encapsulated and linear bound nanocomplexes (1.52 mM), together with the 
calculated percentage binding efficiency.  Figures 3.4-3.7 depict the cytotoxicity profiles of these 
nanoparticles and nanocomplexes in the four cell lines. A similar trend of little or no cytotoxicity 
was observed for the AuNP and Au-CS with the AuNPs showing increased cell viability with 





























Cs Encap pH 7
Cs Linear pH 7
Cs Encap pH 4




showed a greater cytotoxic effect and a dose dependent profile, with encapsulated nanocomposites 
inducing greater cell death (>70% in all cell lines), compared to linear bound nanocomposite. The 
drug controls showed limited cytotoxicity towards the cancerous cell lines, when compared to the 
nanocomposites of Au-CS:5-FU both encapsulated and linear. This data combined illustrates that 
whilst the nanoparticles and nanocomplexes were not cytotoxic to cells, upon the addition of 5-FU 
they become much more efficient drug delivery vectors. The HEK293 cell line was used as a 
control cell line, to test the cytotoxicity of the nanocomposites towards a non-cancerous cell line.  
It was further anticipated that the use of AuNP would reduce the cytotoxic effects in this cell line, 
whilst increasing the overall anticancer activity of the drug towards the non-cancerous cell line. 
AuNP’s did not have any significant cytotoxic action on the HEK293 cell line, the same was true 
for the Au-Cs nanocomplexes. Overall there was in increase in the percentage cell viability from 
ratio 1 to 4 for these complexes. Drug containing nanocomposites, show a decrease in cell viability 
from ratio 1 to 4, indicating a dose dependent profile in the HEK293 cells. This trend is also seen 
in the other three cell lines, with different degrees of cytotoxicity achieved. The encapsulated 
AuNP-CS:5-FU complexes showed the greatest anticancer activity across all four cell lines cell 
lines with close to 70% cell death occurring mostly at the highest concentration. The linear bound 
AuNP-CS:5-FU complexes however displayed the best balance of anticancer activity towards the 
cancerous cell lines and reduced cytotoxic effects in the HEK293 cell line resulting in 
approximately 65% cell death at the highest ratio for the cancerous cell lines and 60 % cell death 
for the HEK293 cell lines compared to the approximately 80% cell death exhibited by the 
encapsulated nanocomplex. However, the nanocomposites consisting of CS:5-FU via 
encapsulation and linear binding methods revealed a lower anticancer activity in all cell lines 
compared to their respective polymer-AuNP:5FU complexes. This clearly indicates that the 
presence of the AuNP in the complex, significantly increased the activity of the anticancer drug. 
This could be due to efficient cellular uptake due to the small size and positive surface charge of 
the nanoparticles, in addition to the slow controlled release of the drug over a period of time, 






Figure 3.4 MTT cytotoxicity assay of nanoparticles and nanocomplexes in the HepG2 cell line.                     
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios 
as laid out in Table 3.1. 
 
 
Figure 3.5 MTT cytotoxicity assay of nanoparticles and nanocomplexes in the Caco-2 cell line.                     
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios 
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Figure 3.6 MTT cytotoxicity assay of nanoparticles and nanocomplexes in the MCF-7 cell line                     
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios 
as laid out in Table 3.1. 
 
 
Figure 3.7 MTT cytotoxicity assay of nanoparticles and nanocomplexes in the HEK293 cell line                     
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios 

















































3.4.7.2    Sulforhodamine B (SRB) Assay 
To correlate the results obtained from the MTT assay, a second cytotoxicity assay was performed 
with the same nanoparticles and nanocomplexes. The SRB cytotoxicity assay is a sensitive, 
quantitative assay which involves the staining of cellular proteins by sulforhodamine B (SRB). 
The SRB dye is an is an anionic aminoxanthene, which binds to the basic amino acid residues of 
proteins through electrostatic interactions under mildly acidic conditions. The SRB assay provides 
a measure of drug induced cytotoxicity, with much greater sensitivity52. Figures 3.8-3.11, depict 
the cytotoxicity profiles for the SRB assay in the four cell lines. A similar trend for AuNP’s and 
Au-CS as in the MTT assay was observed, viz. with an increasing cell viability lined to increasing 
concentration.  However, the AuNP-CS:5-FU nanocomplexes and the CS:5-FU nanocomplexes 
all showed a dose dependent activity with decreased viability across all three cell lines as 
concentration increased. Encapsulated Au-CS:5-FU showed the greatest anticancer activity with 
the exception of the Caco-2 cell line at the highest concentration, and correlates with data from the 
MTT assay. The HepG2 cells (Figure 3.8), least tolerated the nanocomplexes, with a significant 
decrease in the cell viability (~80% cell death) at the highest ratio. Linear bound nanocomposites 
showed lower cell death, indicating a lesser ability to deliver the anticancer agent successfully to 
the cell lines, compared to encapsulated complexes. This is also evident in the Caco-2 and MCF-
7 cell lines. This assay further confirmed that the inclusion of AuNP in the delivery system played 
a significant role in the level of anticancer activity observed, and that encapsulated nanocomplexes 
were more efficient than their linear bound counterparts. The SRB assay results hence correlate 












Figure 3.8 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the HepG2 cell line.                      
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically 




Figure 3.9 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the Caco-2 cell line                      
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically 

























































Figure 3.10 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the MCF-7 cell line                    
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically 
significant, Ratios as laid out in Table 3.1. 
 
 
Figure 3.11 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the HEK293 cell line                 
Data represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically 




















































3.4.8  Mechanism of cell death – Apoptosis studies 
Apoptosis studies was conducted to determine the mechanism of cell death resulting from exposure 
to the two nanocomposites viz. encapsulated and linear bound CS-AuNP:5-FU, which produced 
the most significant anticancer activities in the MTT and SRB assays. The dual acridine 
orange/ethidium bromide (AO/EB) assay allows for the sensitive fluorescent detection of live, 
early and late apoptotic cells and necrotic cells. The principle behind this technique is that acridine 
orange stains live cells, by intercalating with the cell’s DNA to emit a green fluorescence, while, 
ethidium bromide stains dead cells resulting in the emission of a yellow to red fluorescence, which 
is dependent on the stage of apoptosis 53. Hence, viable cells will fluoresce green, with early 
apoptotic cells fluorescing a brighter hue of green, late apoptotic cells will fluoresce orange with 
a condensed chromatin visible, and necrotic cells will also fluoresce orange but with no chromatin 
condensation visible 54.  Apoptotic features were visible in all four of the cell lines (Figure 3.12) 
with the nanocomplexes showing higher levels of apoptotic induction towards the cancerous cell 
lines, as seen from the higher apoptotic indexes calculated (Table 3.3) studies have demonstrated 
that 5-FU does induce apoptosis in a wide range of cell lines,55-58 . The apoptotic index was much 
lower in the control cell line HEK293, compared to the three cancerous cell lines, from the data 
observed in the drug release, the pH microenvironment of a normal cell is not acidic, possibly 
aiding in the slow release of the bioactive agent. Nanocomposites containing encapsulated 5-FU 
showed a higher apoptotic index in all cell lines compared to linear bound nanocomposites. These 
results correlate with the MTT and SRB cytotoxicity assays, in that the encapsulated 
nanocomplexes are more effective than the linear bound counterparts in the delivery of the drug 
5-FU, and inducing anticancer activity.   
 
Table 3.3. Apoptotic indices for the nanocomposites in HEK293, HepG2, Caco-2 and MCF-7 cell lines 




HEK293 0.111 0.10 
HepG2 0.25 0.17 
Caco-2 0.64 0.26 





Control          Encapsulated                          Linear 
 
HEK293 
             




 d            
              
Caco-2 
 






Figure 3.12: Fluorescent images obtained from the dual acridine orange /ethidium bromide apoptosis 
studies in the HEK293, HepG2, Caco-2 and MCF-7 cell lines at 20x magnification. (L= live cells; A= 










3.5  Conclusion 
Gold nanoparticles were successfully synthesized, through chemical reduction and functionalized 
with the cationic polymer chitosan. The conjugation of AuNP to CS through the binding of Au to 
their NH2 and OH groups, was successful as evidenced from the FTIR, UV-vis, TEM and NTA 
analysis. Of the two conjugation methods investigated, encapsulation emerged superior, with good 
colloidal stability, desirable size, higher drug binding efficiency (89.95 %), favorable drug release 
profile and efficient cellular uptake. The cytotoxicity assays further confirmed the above findings, 
with high anticancer activity observed in all cell lines. This study confirmed that the use of 
functionalized gold nanoparticles in drug delivery, enhances the anticancer activity of the bound 
drug, compared to drug delivery on its own or with a polymer. Overall, these nanocomplexes have 
shown to be promising drug delivery systems and warrant further optimization and testing in more 
cell lines and in an in vivo system. 
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The formulation of safe and efficient drug delivery systems, which are able to overcome the many 
limitations and hurdles faced by conventional methods, is seen as the next step towards 
successfully treating diseases such as cancer. Nanoparticles have gained much attention due to 
their desirable characteristics, facile synthesis and their adaptability in applications across various 
fields. Of these nanoparticles, the noble metal gold, has emerged superior due to characteristics 
such as high surface to volume ratio, relative ease of synthesis and low toxicity to name a few. 
Through the chemical reduction of gold (III) chloride trihydrate with sodium citrate, AuNPs were 
synthesized and functionalized with poly-l-lysine (PLL), a cationic polymer and an anticancer 
agent 5-fluorouracil (5-FU). Subsequent nanocomplexes and nanocomposites were fully 
characterized through UV-vis spectroscopy, ICP, FTIR, TEM and nanoparticle tracking analysis 
(NTA).   
Nanocomplexes consisting of PLL:5-FU were synthesized via two methods viz. encapsulation and 
linear binding, followed by their conjugation to AuNPs. Nanocomplexes prepared by the 
encapsulation method displayed better binding and drug release, protection of the drug, and greater 
anticancer activity in the cancer cell lines, HepG2, Caco-2 and MCF-7 compared to the linear 
binding method, probably. Cytotoxicity analysis was carried out using the MTT and SRB assays 
in all cell lines to provide a detailed cytotoxicity profile. Overall, studies revealed that both 
methods of formulation were significantly effective in delivering the anticancer agent to the cancer 
cell lines, with little cytotoxicity observed towards the non-cancer cell line.  
 











The term nanotechnology refers to the creation, synthesis and manipulation of materials on an 
atomic scale, often between 1-100 nm1. The creation of materials on this scale, results in properties 
which are unique to nanoparticles, such as size, charge and solubility2. For this reason, 
nanotechnology is viewed by many as having a promising future for the treatment for cancer, 
considering that the classical forms of treatment, to date have been less than ideal3. Most classical 
anticancer agents such as 5-fluorouracil do not exhibit a specificity towards the tissue they act on, 
and while they have been shown to be effective in killing cancerous tissue, they have also been 
known to cause high levels of toxicity towards healthy tissue, limiting their use at high 
concentrations. This drug specifically has also been shown to present with  low bioavailability and 
solubility4. 
These factors combined resulted in the limited use of these anticancer drugs. Classical therapy 
strategies have also been faced with obstacles, including low accumulation into tumor tissue and 
rapid metabolism, resulting in many therapies being ineffective towards the treatment of cancer5. 
Importantly, the use of nanoparticles in drug delivery have been shown to increase bioavailability, 
and increase retention time. In addition the use of nanoparticles have increased the plasma half-
life  of cytotoxic drugs, while keeping toxicity to a minimun6. These factors have resulted in 
nanoparticle conjugated cytotoxic drugs being able to overcome drug resistance, through 
accumulation of the anticancer agents, in high volumes in the tumor regions7. The ability to 
functionalize different targeting ligands onto the surface of nanoparticles, allow for the delivery of 
specific drugs to organs rich in these ligand specific receptors8.  
The ability to tailor make drug delivery vectors, allow for the use of drugs at much lower 
concentrations, whilst still resulting in significant anticancer activity, and lower cytotoxicity in 
healthy tissue. Encapsulation of many hydrophobic drugs increases their solubility and reduces the 
need for many organic solvents, which have been used in the past to increase the solubility of 
drugs, leading to increased cytotoxicity. Encapsulation offers the added advantage of preventing 
the degradation of the drug in vivo, thereby allowing for smaller concentrations to be used. It is 
known that nanoparticles possess large surface to volume ratios, resulting in larger volumes of 




Various nanoparticles have been investigated for use as drug delivery vehicles including 
liposomes11, 12, carbon nanotubes13, dendrimers,14 selenium15 and metallic nanoparticles such as 
gold16. Gold nanoparticles (AuNPs) have shown potential as drug and gene delivery vectors due 
to their unique optical properties 17, low toxicity and high biocompatibility18 19. AuNP’s present 
with a core which is essentially inert, assisting to its low levels of cytotoxicity observed. They 
have been shown to possess unique properties such as surface plasmon resonance (SPR) and the 
ability to bind amine and thiol groups20, allowing for the conjugation of polymers such as poly-l-
lysine. Gold nanoparticles readily enter the cell through nonspecific receptor mediated 
endocytosis21, resulting in the accumulation of the nanoparticles at the site of the tumor, which 
present with a leaky, mutated vasculature. These properties allow for alternative or combined 
therapies, such as photo thermal ablation22.  
The addition of poly-l-lysine (PLL) serves as a stabilizing agent for synthesized AuNPs23. It is a 
cationic polymer with an abundance of primary amino groups, which are primarily responsible for 
the controlled drug release observed in nanocomposites consisting of PLL24. Poly-l-lysine is a 
biocompatible polymer, which exhibits low toxicity and has a high level of biodegradability25. 
5-Fluorouracil (5-FU), is a broad spectrum anticancer agent, which has been shown to be effective 
against cancer cells.26, however like most cytotoxic drugs it shows little specificity, resulting in 
high cytotoxicity in healthy tissue27.  Using the combination of AuNPs and PLL conjugated to 5-
FU, it was hoped that there would be an increase in anticancer activity towards cancerous cell lines 
and a reduction in the cytotoxicity towards the control cell line. This study involves a comparison 
of conjugation protocols with the encapsulation of 5-FU into AuNP-PLL and linearly bound 
AuNP-PLL:5-FU, to determine, which method offers greater activity of the drug. AuNP-PLL have 
been prepared with and without the drug 5-FU. The prepared nanocomposites have been fully 
characterized using UV-vis, TEM, FTIR, ICP and NTA. In vitro drug release profiles have been 
evaluated, and cytotoxicity studies in all four human cell lines have also been assessed.   
 
4.2. Materials  
Gold (III) chloride trihydrate (Mw: 393.83 g mol
-1, HAuCl4.3H2O), Poly-L-lysine hydrobromide 
(Mw: 1000-5000), Polysorbate 80 (Tween 80, Mw: 1,310 g mol
-1, C64H124O26), Sodium 





Sulforodhamine B (SRB Dye, Mw: 558.67 g mol-1, C27H30N2O7S2), Acridine Orange hemi (zinc 
chloride) salt [3,6-Bis(dimethylamino) acridine hydrochloride zinc chloride double salt] (Mw: 
265.36, g mol-1, C17H19N3), Dialysis Tubing (MWCO= 1000 Daltons) were purchased from Sigma-
Aldrich Chemical Co., (St. Louis, USA). Sodium citrate tribasic dehydrate, phosphate-buffered 
saline tablets [PBS, (140 mM NaCl, 10 mM phosphate buffer, 3 mM KCl)], 3-[(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), ethidium bromide, glacial acetic 
acid, and dimethyl sulfoxide [DMSO], were supplied by Merck (Darmstadt, Germany). The human 
cells, embryonic kidney (HEK293), colorectal adenocarcinoma (Caco-2), hepatocellular 
carcinoma (HepG2) and breast adenocarcinoma (MCF-7) were obtained from the American type 
culture collection (Pty) Ltd, Manassas, Virginia, USA. Sterile Fetal Bovine Serum (FBS) was 
sourced from  Hyclone GE Healthcare (Utah, USA). Eagle’s Minimum Essential Medium 
(EMEM) with L-glutamine (4.5 g ml-1), Penicillin/ Streptomycin/ Amphotericin B (100x) 
antibiotic mixture [Amphotericin B (25 mcg ml-1), NaCl (8.5 mg L-1) Potassium penicillin (10 000 
Units mL-1), Streptomycin sulphate (10 000 mcg ml-1)] and Trypsin-versene-EDTA mixture were 
purchased from Lonza Bio Whittaker (Verviers, Belgium). All sterile tissue culture plasticware 
were supplied by Corning Inc., (New York, USA). Analytical grade reagents and ultrapure (18 
MOhm) water (Milli-Q Academic, Millipore, France) was used throughout. 
 
4.3 Methods 
4.3.1 Preparation of colloidal gold nanoparticles (AuNPs) 
An adaptation of the Turkevich method was used to synthesize the AuNPs , by reduction of Gold 
(III) chloride trihydrate (H[AuCl4]) with sodium citrate (NaC6H5O7). To 25 ml of 18 MOhm water 
at a temperature of 85-95 ˚C, was added with stirring, 375 µl of a 3 x 10-2 M of H(AuCl4) solution, 
and 1 ml of 1% sodium citrate. A color change from a pale yellow to dark blue after 5 minutes and 
eventually to a deep wine red after 15 minutes indicated the formation of the nanoparticles. After 
5 minutes, the solution containing a final concentration of 0.45 x 10-3 M of the colloidal AuNPs, 








4.3.2         Synthesis of 5-FU encapsulate PLL-AuNP nanocomposites 
To 2.5 ml of PLL solution (0.75 mg ml-1 in 2% acetic acid) was added 2.5 ml of 5-FU solution 
(3.8 mM in 18 M Ohm water) with constant mixing. Thereafter, Tween 80 (0.5% v/v) was added, 
and pH maintained between 4.6-4.8.  A PLL: TPP complex of ratio 2:1 (v/v) was then produced by 
the addition of 1.25 ml of TPP. After gentle mixing for 180 minutes, to ensure conjugation of 5-
FU to the nanoparticles, 2 ml of the synthesized colloidal AuNP solution, was added dropwise to 
2 ml of PLL:5-FU nanoparticles under gentle stirring.    
 
4.3.3      Synthesis of 5-FU linear PLL-AuNP nanocomplex  
To 2.5 ml of PLL solution (0.75 mg ml-1) was added approximately 2.5 ml of 5-FU solution (3.8 
mM) and gently stirred for 180 minutes. Thereafter, 2 ml of the AuNP solution was added dropwise 
to 2 ml of PLL:5-FU with stirring for 60 minutes.    
 
4.3.4     UV-vis spectrophotometry analysis 
To confirm the successful synthesis of the AuNPs and AuNPs-PLL, their absorption spectra was 
obtained by UV-vis spectroscopy, and correlated with that provided in literature. The expected 
surface plasmon resonance (SPR) absorption of the gold nanoparticles is at 520 nm, with any shift 
in the absorption spectra indicating successful conjugation of the biomolecule. Solutions were 
sonicated and vortexed, and then measured using a Biomate 3 spectrophotometer (Thermo Fischer 
Scientific Inc., Waltham, Massachusetts, USA).   
 
4.3.5     Transmission Electron Microscopy (TEM) 
The size, uniformity and ultrastructural morphology of all the AuNPs and their nanocomplexes 
were determined by TEM. Approximately, 10 µl of the respective nanoparticle/ nanocomplex 
samples was added to a 400 mesh carbon coated copper grid (Ted Pella Inc. Redding, USA) and 
air dried at room temperature for 1 hour. Samples were then viewed in a JEOL-JEM T1010 (Jeol, 
Tokyo, Japan) electron microscope at 60 000x magnification, with temperature above -150C, and 
at an operating acceleration voltage of 100 kV. Images were captured using the iTEM Soft Imaging 




4.3.6 Nanoparticle Tracking Analysis (NTA) 
To determine the accurate size distribution and zeta potential of all nanoparticles and 
nanocomplexes, analysis was performed at 25C using a laser based NTA system (Nanosight NS-
500, Malvern Instruments, UK). Samples were diluted 1:500 in 18 MOhm water, and 1 ml of each 
sample was evaluated, after the instrument was primed, flushed, and the camera zero position set. 
All samples were run in triplicate.             
 
4.3.7     Inductively coupled plasma-optical emission spectroscopy analysis (ICP) 
The accurate Au concentration present in the prepared colloidal AuNP solution was determined 
through inductively coupled plasma-optical emission spectroscopy (ICP-OES). This was 
performed on a Perkin Elmer optima 5300 DV optical emission spectrometer. A standard curve 
between 1 – 20 ppm, was set up using a standard Au stock solution of 100 ppm.  
 
 4.3.8     Fourier transform infra-red analysis (FTIR) 
FTIR was employed to confirm the presence of essential groups and bonds in Au-PLL, as displayed 
in the obtained spectra. The spectrum was run using 200 µl of the respective sample in a Spectrum 
Perkin Elmer spectrophotometer, and the respective IR spectra were obtained using Spectrum 
Analysis Software. 
 
4.3.9     Encapsulation efficiency  
Approximately, 2 ml of respective encapsulated and linear Au-PLL:5-FU nanocomplexes were 
dialyzed (MWCO=1000 Da), against 15 ml PBS for 12 hours at 37˚ C. Absorbance readings at 
266 nm, of 1 ml samples were taken pre-dialysis, and at the end of the 12-hour incubation. The 
encapsulation efficiency of 5-FU was determined using the following equation:           
Encapsulation efficiency (%) = (Total 5-FU)- (Bound 5-FU)/ (Total 5-FU) x 100  
 
4.3.10     Drug release studies 
Drug release studies were performed at pH 4.0 and pH 7.0, to assess the ability of the 




encapsulated and linear, were dialyzed (MWCO= 1000 Da) against 5 ml PBS for 7 hours at 37˚C. 
Hourly samples of 2 µl sample was removed and analyzed on a Nanodrop oneC, UV-vis 
spectrophotometer (Thermo Fischer Scientific Inc.,Waltham, Massachusetts,USA) at 266 nm. 
Readings obtained were used to generate a drug release profile for the respective nanocomplexes 
under the different pH conditions. 
 
4.3.11      Reconstitution, propagation and maintenance of cell lines in vitro   
Animal cell culture studies were conducted under sterile conditions in an Airvolution Class II 
biosafety laminar flow hood. All media and cell culture reagents were first warmed to 37˚C in a 
water bath, prior to any procedure. Cells were obtained from cryopreserved stick and thawed at 
37˚C and then centrifuged at 3000 rpm for 60 seconds. The cell pellet was re-suspended in 1 ml of 
complete medium (EMEM supplemented with 10% (v/v) FBS and antibiotics (100 U ml
-1 
Penicillin, 100 µg ml-1 streptomycin), and then dispensed into 25 cm2 tissue culture flasks 
containing 5 ml of medium, and incubated at 37˚C in a HEPA class 100 Steri-Cult CO2 incubator 
(Thermo-Fisher Corporation, Waltham, Massachusetts, USA). The medium of reconstituted cells 
was changed after 24 hours to remove any traces of the cryopreservatant. The growth of cells was 
routinely monitored under a Nikon TMS inverted microscope (Nikon Corp, Tokyo, Japan). The 
old medium was replenished, cells subcultured for propagation or cell culture assays or cells were 
cryopreserved, depending on cell growth and assay requirement. 
 
4.3.12     Trypsinization  
After cells were washed with 5 ml of PBS (pH 7.5), 1 ml of trypsin-versene was added to cells. 
Trypsinization was monitored under an inverted microscope. Once cells had “rounded off”, 
trypsinization was halted by the addition of 1 ml medium containing serum that inhibits the enzyme 
action. To dislodge all the cells, the flask was gently tapped against the palm of the hand. Cells 
were then split into separate culture flasks, multiwell plates or alternatively cryopreserved. 
 
4.3.13     Cryopreservation  
After trypsinization, cells were pelleted by centrifugation at 3000 rpm for 1 minute, then re-




into sterile 2 ml cryogenic vials. The vials were inserted into a NalgeneTM “Mr Frosty” Cryo 1˚C 
freezing container, containing isopropanol. Cells were frozen at a rate of -1 ̊ C per minute to a final 
temperature of -70 ˚C, and then stored in a -80 ˚C biofreezer (Nuaire, Lasec Laboratory and 
Scientific equipment), for short term storage or in liquid N2 for long term storage. 
 
4.3.14      MTT cytotoxicity assay 
Trypsinized cells were plated into clear 96-well plates at seeding densities between 2.4 x 104 - 2.9 
x 104 cells per well, and incubated at 37˚C for 24 hours to allow for attachment of cells. The old 
medium was then replenished with 200 µl fresh complete EMEM, followed by addition of the 
AuNP, Au-PLL, Au-PLL:5-FU encapsulated, Au-PLL:5-FU linear and PLL:5-FU nanocomplexes 
at concentrations set out in Table 4.1. Positive controls (100 % survival), containing cells only 
were included and assays were conducted in triplicate. Cells were incubated for 48 hours at 37˚C 
in 5% CO2, followed by removal of the old medium and the addition of 100 µl fresh medium and 
100 µl of MTT reagent (5 mg/ml in PBS).  The cells were incubated for a further 4 hours at 37 ˚C, 
after which the MTT infused medium was removed, and 200 µl of DMSO was added to each well, 
to solubilize the insoluble formazan crystals. Absorbance was then read at 570 nm, on a Mindray 
MR-96A microplate reader (Vacutec, Hamburg, Germany), using DMSO as a blank. The cell 
viability (%) was calculated using the following equation:  
(Abs of treated – Abs of control/ Abs of control) x 100%. 
 
 








Encapsulated     
5-FU control 
PLL Linear      
5-FU control 
 1:0 1:1 2:1:1 2:1:1 1:1 1:1 
1 0.134 µg 3.88 µg 0.275 µg 0.275 µg 1.306 µg 1.089 µg 
2 0.268 µg 7.77 µg 0.549 µg 0.549 µg 2.612 µg 2.178 µg 
3 0.402 µg 11.7 µg 0.884 µg 0.884 µg 3.919 µg 3.267 µg 






4.3.15     SRB cytotoxicity assay 
This samples were set up as for the MTT assay (4.3.14, Table 4.1). Following the 48-hour 
incubation, 50 µl of TCA (50%) was gently layered onto the cells, taking care not to dislodge cells. 
After a 1 hour at 4˚C incubation, cells were washed (3x) with 18 MOhm water, to remove excess 
serum and fixative agent. Plates were then dried at 40˚C for 1 hour, followed by the addition of 
100 µl of SRB dye (0.4% w/v in 1% acetic acid) to each well. This was then incubated for 30 
minutes at room temperature, in the dark. Excess dye was removed by washing (3x) with 1% acetic 
acid, and any protein bound dye was solubilized with 200 µl of 10 mM Tris base. Absorbance’s 
were obtained using a Mindray MR-96A microplate reader at 565 nm using Tris base as the blank.  
Cell viability was calculated is in 4.3.14. 
 
4.3.16     Mechanism of cell death - Apoptosis Assay 
The dual acridine orange and ethidium bromide system (1:1v/v of a 100 mg.ml
-1 in PBS stock) 
employed, is a rapid fluorescent technique for the detection of cell apoptosis in vitro. Cells were 
trypsinized and seeded into clear 24-well plates at a density of 1.2 x 105 cells per well, and 
incubated at 37˚C for 24 hours. Medium was thereafter replenished with 400 µl of fresh medium, 
0.920 µg and 1.040 µg respective nanocomplexes (Au-PLL:5-FU encapsulated and linear) added. 
Positive controls containing cells only were used. Assay was done in triplicate. After a 48-hour 
incubation at 37˚C in 5% CO2, cells were washed with 100 µl of cold PBS, followed by the addition 
of 15 µl of the dye solution to each well. Cells were viewed under an Olympus fluorescent 
microscope (200x magnification), fitted with a CC12 fluorescent camera (Olympus Co., Tokyo, 
Japan). The apoptotic indices were calculated using the following equation:  
Apoptotic Index = Number of Apoptotic cells/ total number of cells counted.   
 
4.3.17     Statistical analysis 
All data is presented as mean ± standard deviation (± SD n=3). The Dunnetts post hoc test was 
used for the MTT and SRB assay. Statistical significance of the tests was set at **p<0.01 and 
*<0.05. Each of the experimental values were compared to their corresponding control. GraphPad 





4.4     Results and discussion 
4.4.1 UV-vis studies 
The UV-vis spectra of the AuNPs, and AuNP-PLL are depicted in Figure 4.1. Due to extreme 
aggregation of nanocomplexes containing 5-FU, these UV spectra could not be easily obtained. 
However further characterization studies viz. TEM and NTA were able to confirm the successful 
binding of 5-FU to AuNP-PLL. The AuNPs possess unique optical properties, making it possible 
to estimate the approximate size of the nanoparticles synthesized. Analysis revealed a single peak 
for AuNPs at 522 nm (Figure 4.1), and according to literature a peak in the 522- 525 nm range 
corresponds to the surface plasmon excitation of small, spherical gold nanoparticles which are 
monodispersed and well separated28. The AuNP absorbance value at 522 nm was 1.266, providing 
an indication of the amount of gold present in the colloidal solution. The AuNP-PLL 
nanocomplexes presented with a single peak at 526nm, indicating that the AuNPs were 
successfully conjugated to PLL, which was further confirmed using TEM (Figure 4.2 B). 
 

























4.4.2  TEM Imaging 
The TEM analysis of the AuNPs and their nanocomplexes are shown in Figure 4.2A-D. Figure 
4.2A clearly shows the AuNPs, as being uniform in shape, with good polydispersity, and very little 
aggregation of the nanoparticles. The AuNP-PLL (Figure 4.2B), can be observed possessing a 
AuNP core embedded in a matrix of PLL. One of the challenges of using PLL is its tendency to 
agglomerate. A high level of agglomeration suggests that due to the high loading capacity of the 
AuNPs, a single PLL molecule may be bound to more than one AuNP, contributing to an increase 
in agglomeration, a study reported the aggregation of poly-l-lysine which are cationic and the 
negatively charged nanoparticles. It was discovered that soon after the incorporation of poly-l-
lysine with AuNP’s, there was the formation of distinct, submicrometer spherical aggregates. 
Studies involving light scattering revealed that the particles increase in size with an increase in 
time indicating a dynamic flocculation process29. The results from TEM correlate well with this 
study. The level of agglomeration seen in Figure 4.2B, indicates that due to the increase in size, 
the nanoparticles may encounter difficulties with respect to cellular uptake, which may impact on 
the outcomes of the cell viability tests. From the two 5-FU containing nanocomplexes (Figure 
4.2C-D), the encapsulation method appears to have produced nanocomplexes with a greater level 
of dispersion, than in the linear method, with these particles tending to aggregate more. This is 
possibly due to the binding of a 5-FU molecule to more than one nanoparticle, since linear binding 
results in the 5-FU molecules being exposed on the exterior of the nanocomplex.  However, both 








Figure. 4.2     TEM images of (A) Au nanoparticles, (B) AuNP-PLL, (C) Encapsulated AuNP-PLL:5-FU 




4.4.3 Nanoparticle tracking analysis (NTA) 
NTA provides an accurate assessment of the size distribution, zeta potential and colloidal stability 
of nanoparticles in solution. The respective nanoparticle and nanocomplex sizes and zeta potential 
values are shown in Table 4.2. These results indicate that the AuNPs had a mean diameter of 65.9  
9.8 nm, confirming successful synthesis of AuNPs under 100 nm. Zeta potential analysis provides 
an indication of the long-term stability of the colloidal suspension, a property that is extremely 
important in vivo. A high zeta potential value generally correlates to good colloidal stability. 
Essentially, zeta potential analysis is a measure of the electrostatic repulsive forces which are 
present between similarly charged particles in a suspension.  
The AuNPs had a zeta potential value of -7.3 mV, which is a relatively low, however on addition 
of poly-l-lysine, an increase to + 37.2 mV was recorded. This shift from an overall negative zeta 
potential value to a positive value is an indication of strong ionic bonds formed between the surface 
of the AuNP and the polymer and correlates well with the results from UV-vis and TEM studies. 
Furthermore the data correlates with a study in which the concentration of cationic polymer was 
varied and respective analysis of the zeta potential was carried out, it revealed that as the 
concentration of polymer increased so did the zeta potential30. The polymer was incorporated onto 
the AuNP for two reasons viz. (1) to act as a stabilizing agent and, (2) to serve as a link between 
the AuNPs and the anionic drug 5-FU. The shift in zeta potential values also indicate that PLL was 
successful in stabilizing the nanoparticle, due to larger repulsive forces now existing between the 
nanoparticles. 
The increase in size from 65.9 to 95.3 nm is a further confirmation of PLL successfully binding to 
the AuNP. Upon addition of encapsulated and linear bound 5-FU, the zeta potential value 
decreased from + 37.2 mV to + 9.7 mV and + 12.8 mV respectively, showing a correlation between 
binding efficiency and zeta potential. Size distribution analysis revealed that there was little 
difference in size, between the two types of nanocomplexes upon addition of 5-FU with sizes of 
nanocomposites being 101.5 nm and 104.6 nm respectively. This was also noted from the TEM 
images. There was a slight increase in size for the AuNP-PLL:5-FU nanocomplexes, due to the 
matrix of PLL- gold nanoparticle flocculation, making it difficult for the drug to be encapsulated 




A large zeta potential value is important; however it is not the sole determining factor for a delivery 
vector, with the ability of a nanocomplex to successfully release the anticancer drug under 
appropriate conditions is equally important. Hence, drug release studies were performed 
 
Table 4.2. Size distribution and Zeta potential analysis of AuNP and its nanocomplexes. 
Sample Nanoparticle size (nm) Zeta potential (mV) 
AuNP 65.9    9.8 -7.3      1.6 
AuNP-PLL 95.3    12.2 +37.2  1.7 
AuNP-PLL:5-FU encapsulated 101.5    1.5 +9.7     1.3 
AuNP-PLL:5-FU linear 104.6    3.6 +12.8    2.9 
 
4.4.4  ICP-OES and FTIR analysis 
The ICP analysis performed could confirm the concentration of the synthesized AuNP. The use of 
FTIR confirmed the presence of PLL and hence its successful conjugation to the AuNP. The 
complete FTIR spectrum is shown in Appendix B. The FTIR spectra displayed C-O stretching at 
~ 1070 cm-1, C-O-C stretching at ~ 1260 cm-1, CH2 bending at 1416 cm
-1, a peak of NH3
+ at ~ 
1568, C=O and N-H bending at ~ 1655 cm-1. These results correspond well with the peak of pure 
PLL with minor differences as a result of the interaction with the gold nanoparticles31. 
 
4.4.5 Encapsulation/ binding efficiency  
To determine the efficacy of the two binding methods of 5-FU, samples of the respective 
nanocomplexes were analyzed by UV-vis spectrometry, before and after dialysis (MWCO= 1000 
Da), which was utilized to remove any unbound 5-FU from the nanocomplexes. The amount of 
free drug was calculated from absorption measurements, with the observed differences in 
absorptions providing an indication of the amount of drug incorporated into nanocomplex. The 
binding efficiency in the encapsulation method was calculated to be 61.43%, whilst the linear 
method provided a binding efficiency of 53.45%. Although, binding above 60% for the can be 






4.4.6  Drug release studies 
Drug release analysis were performed spectrophotometrically, under pH conditions of 7.0 and 4.0, 
to determine the ability of the nanocomposites to protect and release the 5-FU. In addition to 
cancerous cells having a leaky cell wall structure, which aids in the entry of nanocomposites, they 
have been shown to have a lower pH when compared to normal tissue32. Many tumors tend to be 
hypoxic, resulting in a reduction of mitochondrial oxygen consumption and a decrease in the level 
of ATP production. A decrease in the levels of ATP influences the transport systems involved 
within cancerous cells. This results in the breakdown of the NA+ a and K+ gradients, depolarization 
of membranes, an increase in the concentration of Ca2+ and decreased cytosolic pH. These factors 
contribute towards the formation of acidosis in cancerous cells33. A study performed by34, states 
that at a pH around 4-5,  5-FU is released quickly and continuously. The drug 5-FU has been 
shown to have an absorbance peak between 266 - 271 nm 35. It is more favorable in therapy for the 
drug to be delivered continuously, over a period of time rather than in a single dose36. At a pH of 
7.0, the linearly bound nanocomplex released the drug progressively over time, compared to the 
encapsulated nanocomplex, which showed a slower, more restrained drug release profile.  
If nanocomposites release the drug in high volumes under neutral pH, it may result in severe and 
unwanted side effects. At a pH of 4.0, a more controlled release was observed for the encapsulated 
nanocomplex, compared to the linearly bound nanocomplex. This provides an indication that the 
nanocomplex will be able to effectively release the drug under the acidic conditions in cancerous 
cells. The 5-FU encapsulated nanocomplexes was shown to be more effective in binding the drug 
in higher volumes and releasing the drug safely under the appropriate conditions. Both 
nanocomplexes (encapsulated and linear) released approximately, 22% and 41% of the drug 





Figure. 4.3 Drug release profile of nanocomposites under pH 4.0 and 7.0 
 
4.4.7  In vitro Cytotoxicity Studies 
4.4.7.1  MTT Assay 
To test the efficiency of the drug loaded nanocomposites in curbing the proliferation of cancerous 
cells, MTT assays were carried out on three cancer cell lines (HepG2, Caco-2 and MCF-7) and 
one control non-cancer cell line (HEK293). This assay is a rapid, quantitative, colorimetric assay 
for determination of the anticancer activity and cytotoxicity of compounds, and in this case 
nanocomplexes. The principle of the assay is that viable cells will have metabolically active 
mitochondria, where the cellular oxidoreductase enzymes under specified conditions will catalyze 
the reduction of the MTT tetrazolium salt into an intensely colored, insoluble formazan product. 
Gold nanoparticles have been investigated as drug delivery vectors, due to their relative non-
toxicity due to the presence of a chemically inert core37. 
Besides positive cell controls the use of PLL:5-FU controls without AuNPs were evaluated. The 
cytotoxicity profiles of the nanoparticles and nanocomposites are depicted in Figures 4.4 - 4.7. The 
AuNPs in particular did not show cytotoxicity as expected, and the cell viability increased with 
increasing AuNP concentration. Numerous studies including Shukla et al20., Yen et al38, 39.,   At 
the highest ratio, cell viability was actually greater than 100%, which could be indicate that the 
AuNPs had some growth promoting effect on the cells. However, according to Jaszczyszyn and 
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cytosolic or microsomal enzymes. The AuNPs could also have interfered with the enzyme activity 
leading to an increased absorbance, indicating increased cell survival. Interaction of tested 
compounds with the MTT is also possible resulting in increased formazan production and higher 
absorbances40, 41. The AuNP-PLL nanocomplex also displayed low cytotoxicity. Therefore, any 
observed cytotoxicity of the drug containing nanocomplexes would not be due to the presence of 
the AuNPs or AuNP-PLL.  
The cytotoxicity of the AuNP-PLL:5-FU nanocomplex (encapsulated and linearly bound) (Figures 
4.4 – 4.7) is dose dependent, with encapsulated PLL-nanocomplexes inducing greater cell death 
(>70% in HepG2 and HEK293 cells), compared linear bound nanocomposites. This is contrary to 
reports that PLL-nanocomposites due to aggregation would have greater difficulty entering the 
cell. The encapsulated nanocomplexes showed far greater anticancer activity across all three of the 
cancerous cell lines, indicating that the encapsulation method is better for 5-FU delivery, this has 
been demonstrated in previous studied and correlates well with the data42, 43. However, the 
nanocomplexes prepared by the linear method also showed significant activity, illustrating that 
both methods are potent enough for anticancer therapy. This data combined illustrates that while 
AuNP and AuNP-PLL were not cytotoxic to cells, upon the addition of 5-FU they become efficient 
drug delivery vectors, these results correlate well with 44. The PLL-5FU controls also showed 
limited cytotoxicity towards the cancer cells, reinforcing the notion that the combination of AuNP 
and PLL, significantly improved the anticancer activity of 5-FU.  
The encapsulated nanocomplexes did exhibit much cytotoxicity towards the HEK293 cell line 
(Figure 4.5), with a decrease in cell viability from ratios 1 – 4 noted. This can be observed as a 
common trend across all four cell lines, with varying degrees of cytotoxicity attained. The 
encapsulated PLL-AuNP:5-FU nanocomplex displayed the best anticancer activity in the HepG2 
cell line resulting in >70% cell death at the highest ratio. The differences in cytotoxicity levels 
observed can be attributed to the fact that the encapsulated nanoparticles offer a greater degree of 
protection for the drug, compared to the linear nanocomplexes. Hence, the drug once delivered to 
the cancer cells, is released under acidic conditions as evidenced by the drug release studies, 





Figure 4.4 MTT Cytotoxicity assay of nanoparticles and nanocomposites in the HepG2 cell line. Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios as 
laid out in Table 4.1. 
 
 
Figure 4.5 MTT Cytotoxicity assay of nanoparticles and nanocomplexes in the HEK293 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios as 























































Figure 4.6   MTT Cytotoxicity assay of nanoparticles and nanocomplexes in the Caco-2 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios as 




Figure 4.7   MTT Cytotoxicity assay of nanoparticles and nanocomplexes in the MCF-7 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, Ratios as 



















































4.4.7.2      Sulforodhamine B (SRB) Assay 
The SRB cytotoxicity assay was carried out with the same samples to assess whether there was 
any significant correlation with the results obtained from the MTT assay. This is because the SRB 
assay provides a more sensitive measure of drug induced cytotoxicity45. This is a quantitative 
assay, in which cellular proteins are stained by the SRB dye electrostatically binding to the basic 
amino acid residues present in proteins.  
From Figures 4.8-4.11, it can be noted that a similar trend exists as for the MTT assay, with AuNP 
and AuNP-PLL complexes not exhibiting much cytotoxicity in all cell lines, and upon increasing 
nanoparticle concentration, there was a concomitant increase in cell viability. Overall, greater cell 
viability was observed with the SRB assay, compared to the MTT assay, and any observed 
cytotoxicity attributed to the presence of the anticancer agent 5-FU. 
The respective nanocomplexes containing 5-FU exhibited the typical dose dependent activity, 
resulting in a decrease in cell viability across all three cell lines, with increase concentration. The 
encapsulated nanocomplexes displayed a greater level of cytotoxicity, compared to their linear 
counterparts.  This closely correlates with the results from the MTT assay. Both the encapsulated 
and linear nanocomplexes were able to efficiently deliver the 5-FU and bring about a decrease in 
cell viability, with the latter to a lesser extent. The encapsulated nanocomplex was most effective 
in the HepG2 cell line, indicating some cell specificity. These results confirm that the inclusion of 
AuNPs in a drug delivery system, can be beneficial, as in this case it resulted in an increase in 
cytotoxicity.  
Both AuNP or AuNP-PLL were here again well tolerated by the HEK293 cells producing little or 
no cytotoxicity. Overall, both the MTT and SRB assays showed good correlation, and firmly 






   
Figure 4.8 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the HepG2 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, 
Ratios as laid out in Table 4.1. 
 
 
Figure 4.9 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the Caco-2 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, 






















































Figure 4.10 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the MCF-7 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, 
Ratios as laid out in Table 4.1. 
 
 
Figure 4.11 SRB cytotoxicity assay of nanoparticles and nanocomplexes in the HEK293 cell line Data 
represented as means ± SD (n=3), * p<0.05, **p<0.01 were considered statistically significant, 



















































4.8  Mechanism of cell death – Apoptosis studies 
Apoptosis is a programmed cell death and eliminates cells during normal development, and 
prevents the over-proliferation of cells as in the case of cancer. To further correlate observed 
cytotoxicity with the respective nanocomplexes, the mechanism of cell death using an apoptosis 
assay was performed.  Some apoptotic features were visible in the cell lines, indicating these 
nanocomplexes were able to induce apoptosis in the specific cell lines. The calculated apoptotic 
indices are outlined in Table 4.3. Encapsulated nanocomplexes showed higher levels of apoptotic 
induction in the cancer cell lines, as inferred from the higher apoptotic index. This correlates well 
with the data from the MTT and SRB assays. Studies have indicated that 5-Fluorouracil induces 
apoptosis46-49, this correlates well with our results, also indicating that the drug was delivered into 
the cell.     
The two dyes used in the assay stain cells from green to red depending on the viability of the cell. 
Acridine orange stains live and dead cells, while ethidium bromide, stains cells with permeable 
membranes that allow it to enter and stain the DNA.  Hence due to a combination of the two dyes, 
live cells stain green (L), early apoptotic cells (EA) stain a brighter green, late apoptotic cells (LA) 
appear orange with condensed chromatin. and necrotic cells (N) also stain orange but have no 
condensed chromatin. 
 




Au-PLL:5-FU Encapsulated Au-PLL:5-FU Linear 
HEK293 0.0625 0.0551 
HepG2 0.14 0.132 
Caco-2 0.18 0.15 
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Figure 4.12: Fluorescent images obtained from the dual acridine orange /ethidium bromide apoptosis 
studies in the HEK293, HepG2, Caco-2 and MCF-7 cell lines at 20x magnification. (L= live cells; A= 










4.9  Conclusion 
Successful AuNP synthesis, functionalization with PLL and binding of 5-FU was achieved and 
confirmed. From the two 5-FU binding methods, encapsulation of 5-FU in PLL produced higher 
binding efficiencies (61.43%), and a more sustained drug release profile. The cytotoxicity assays 
conducted further confirmed the above findings, with cell selectivity and a dose dependent activity 
observed. Furthermore, the addition of gold into the delivery system significantly enhanced the 
anticancer activity of the drug especially in the cancer cell lines tested. Overall, this AuNP based 
drug delivery system has shown immense promise, which augurs well for future in vivo studies. 
However, further optimizations and more cell lines need to be tested to determine the overall 
pharmacokinetic profile of the system. 
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5.1 Conclusion  
The emergence of new drug delivery systems has increased over the past three decades and show 
promise to continue on this trajectory, due to advances in nanotechnology and the development of 
new material. The application of nanomaterial in therapeutics and nanomedicine requires further 
research if they are going to be effective in in vivo applications. Gold nanoparticles (AuNPs) have 
the potential to form a skeleton around which an efficient and safe drug delivery system can be 
designed. Other systems such as liposomes have shown promise in vitro, however have fallen short 
in many clinical trials. It is hoped that due to their low toxicity, high loading capacity, ease of 
synthesis and functionalization, AuNPs could prove to be more efficient in vivo. The results 
obtained in this study provides an insight into the potential of these nanoparticles for future in vivo 
and in vitro applications, highlighting the areas in the study that can be further researched. 
In this study, spherical, colloidally stable AuNPs of small size (<100 nm) were successfully 
synthesized. Functionalization of AuNPs with cationic polymers of chitosan and PLL respectively, 
were achieved, with both showing greater stability, efficient binding (encapsulation and linear) of 
the anticancer drug, 5-FU, controlled drug release, and favorable cellular uptake probable due to 
the positive charges imparted by the polymers reacting with the negatively charged cell surface. 
This study has successfully demonstrated that these functionalized AuNPs can be used to 
successfully deliver anticancer drugs to different cell lines. In addition, the AuNPs were seemingly 
non-toxic to any of the human cell lines studied. 
Both the AuNP-CS:5-FU and AuNP-PLL:5-FU nanocomplexes, were able to elicit significant 
cytotoxicity in vitro, in both a cell specific and a dose dependent manner. Although, the drug 
encapsulation method performed slightly better than the linear binding method for both polymers, 
both methods produced noteworthy results which can be built upon. Overall, AuNP-CS:5-FU 
nanocomplexes were shown to be more effective as drug delivery carriers, compared to their PLL 
counterparts. Furthermore, it is apparent that the addition of AuNP to the delivery system resulted 
in an increase in anticancer activity, as evidenced from the cytotoxicity studies. 
The results strongly suggest that these nanocomplexes possess the potential to become efficient 




of diseases such as cancer, as well as improving the delivery of other drugs and biomolecules 
across the blood brain barrier to aid in conditions such as depression, anxiety and other mental 
conditions.     
Further research and optimizations to make the nanocomplexes more efficient are warranted. 
Future work could involve the designing of a targeted delivery system capable of delivering 
multiple drugs efficiently, with controlled release profiles. A dual treatment system, using a 
combination of drug delivery and photo thermal ablation therapy is also very appealing, and should 
be considered. The attachment of polymers such as poly-ethyleneglycol for steric stabilization of 
the nanoparticle, which shields and protects it, allowing for its prolonged circulation time in vivo, 
should be attempted.  Lastly, the mechanism involved in cellular uptake, intracellular trafficking, 
and the overall fate of the AuNPs after the drug has been delivered need to be evaluated. All this 
information will add to the designing of a safe, stable and efficient drug delivery system of the 
future.  
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